WO2019015593A1 - Composé de pyrimidopyridone ou pyridopyridone et utilisation correspondante - Google Patents
Composé de pyrimidopyridone ou pyridopyridone et utilisation correspondante Download PDFInfo
- Publication number
- WO2019015593A1 WO2019015593A1 PCT/CN2018/096009 CN2018096009W WO2019015593A1 WO 2019015593 A1 WO2019015593 A1 WO 2019015593A1 CN 2018096009 W CN2018096009 W CN 2018096009W WO 2019015593 A1 WO2019015593 A1 WO 2019015593A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- methyl
- amino
- pyrimidin
- phenyl
- pyrido
- Prior art date
Links
- -1 pyridopyridone compound Chemical class 0.000 title claims abstract description 176
- IAAQUOVTPAMQCR-UHFFFAOYSA-N 1h-pyrido[3,2-d]pyrimidin-2-one Chemical compound C1=CC=C2NC(=O)N=CC2=N1 IAAQUOVTPAMQCR-UHFFFAOYSA-N 0.000 title claims abstract description 34
- 150000001875 compounds Chemical class 0.000 claims abstract description 63
- 150000003839 salts Chemical class 0.000 claims abstract description 60
- 229940002612 prodrug Drugs 0.000 claims abstract description 30
- 239000000651 prodrug Substances 0.000 claims abstract description 30
- 230000035772 mutation Effects 0.000 claims abstract description 20
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims abstract description 17
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims abstract description 16
- WDHAAJIGSXNPFO-UHFFFAOYSA-N 8h-pyrido[2,3-d]pyrimidin-7-one Chemical compound N1=CN=C2NC(=O)C=CC2=C1 WDHAAJIGSXNPFO-UHFFFAOYSA-N 0.000 claims description 214
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 185
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 122
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 102
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 claims description 66
- QLNJFJADRCOGBJ-UHFFFAOYSA-N propionamide Chemical compound CCC(N)=O QLNJFJADRCOGBJ-UHFFFAOYSA-N 0.000 claims description 56
- LKJPYSCBVHEWIU-UHFFFAOYSA-N N-[4-cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methylpropanamide Chemical compound C=1C=C(C#N)C(C(F)(F)F)=CC=1NC(=O)C(O)(C)CS(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-UHFFFAOYSA-N 0.000 claims description 48
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 36
- 125000005842 heteroatom Chemical group 0.000 claims description 35
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 28
- 229940080818 propionamide Drugs 0.000 claims description 28
- 229910052739 hydrogen Inorganic materials 0.000 claims description 27
- 206010028980 Neoplasm Diseases 0.000 claims description 26
- 239000003814 drug Substances 0.000 claims description 26
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 24
- 229910052736 halogen Inorganic materials 0.000 claims description 22
- 150000002367 halogens Chemical class 0.000 claims description 22
- 125000000623 heterocyclic group Chemical group 0.000 claims description 22
- 229910052799 carbon Inorganic materials 0.000 claims description 19
- 125000001424 substituent group Chemical group 0.000 claims description 19
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 18
- 102200048928 rs121434568 Human genes 0.000 claims description 18
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 13
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 13
- 239000000460 chlorine Substances 0.000 claims description 12
- 239000001257 hydrogen Substances 0.000 claims description 12
- 229920006395 saturated elastomer Polymers 0.000 claims description 12
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims description 11
- 238000002360 preparation method Methods 0.000 claims description 11
- 125000004195 4-methylpiperazin-1-yl group Chemical group [H]C([H])([H])N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 claims description 10
- 125000003386 piperidinyl group Chemical group 0.000 claims description 10
- 125000003118 aryl group Chemical group 0.000 claims description 9
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 9
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 9
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 9
- 150000001408 amides Chemical class 0.000 claims description 8
- 229910052801 chlorine Inorganic materials 0.000 claims description 8
- 229940121647 egfr inhibitor Drugs 0.000 claims description 8
- 201000011510 cancer Diseases 0.000 claims description 7
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 7
- 229910052731 fluorine Inorganic materials 0.000 claims description 7
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims description 7
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 7
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims description 6
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 6
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims description 6
- 235000013877 carbamide Nutrition 0.000 claims description 6
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 6
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 6
- 150000002148 esters Chemical class 0.000 claims description 6
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims description 6
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 6
- 125000004483 piperidin-3-yl group Chemical group N1CC(CCC1)* 0.000 claims description 6
- 238000007363 ring formation reaction Methods 0.000 claims description 6
- 150000003457 sulfones Chemical class 0.000 claims description 6
- 150000003462 sulfoxides Chemical class 0.000 claims description 6
- VIRUJHDGKJVVOU-GSDHBNRESA-N 6-(2-chlorophenyl)-5-methyl-2-[3-methyl-4-[(1S,4S)-5-methyl-2,5-diazabicyclo[2.2.1]heptan-2-yl]anilino]-8-[(3S)-1-propanoylpiperidin-3-yl]pyrido[2,3-d]pyrimidin-7-one Chemical compound ClC1=C(C=CC=C1)C1=C(C2=C(N=C(N=C2)NC2=CC(=C(C=C2)N2[C@@H]3CN([C@H](C2)C3)C)C)N(C1=O)[C@@H]1CN(CCC1)C(CC)=O)C VIRUJHDGKJVVOU-GSDHBNRESA-N 0.000 claims description 5
- 206010006187 Breast cancer Diseases 0.000 claims description 5
- 208000026310 Breast neoplasm Diseases 0.000 claims description 5
- KWTQNPKOKNNKGT-VWLOTQADSA-N ClC1=C(C=CC=C1)C1=C(C2=C(N=C(N=C2)NC2=CC(=C(C=C2)N2CCN(CC2)C)C)N(C1=O)[C@@H]1CN(CCC1)C(CC)=O)C Chemical compound ClC1=C(C=CC=C1)C1=C(C2=C(N=C(N=C2)NC2=CC(=C(C=C2)N2CCN(CC2)C)C)N(C1=O)[C@@H]1CN(CCC1)C(CC)=O)C KWTQNPKOKNNKGT-VWLOTQADSA-N 0.000 claims description 5
- YPWPSPQUNUXGTD-DEOSSOPVSA-N ClC1=C(C=CC=C1)C1=C(C2=C(N=C(N=C2)NC2=CC(=C(C=C2)N2CCNCC2)C)N(C1=O)[C@@H]1CN(CCC1)C(CC)=O)C Chemical compound ClC1=C(C=CC=C1)C1=C(C2=C(N=C(N=C2)NC2=CC(=C(C=C2)N2CCNCC2)C)N(C1=O)[C@@H]1CN(CCC1)C(CC)=O)C YPWPSPQUNUXGTD-DEOSSOPVSA-N 0.000 claims description 5
- KOOZQKOTLUSFHU-SANMLTNESA-N ClC1=C(C=CC=C1)C1=C(C2=C(N=C(N=C2)NC2=CC(=C(C=C2)N2CN(CCCC2)C)C)N(C1=O)[C@@H]1CN(CCC1)C(CC)=O)C Chemical compound ClC1=C(C=CC=C1)C1=C(C2=C(N=C(N=C2)NC2=CC(=C(C=C2)N2CN(CCCC2)C)C)N(C1=O)[C@@H]1CN(CCC1)C(CC)=O)C KOOZQKOTLUSFHU-SANMLTNESA-N 0.000 claims description 5
- XNBXJQDCLBLGOC-QHCPKHFHSA-N ClC1=C(C=CC=C1)C1=C(C2=C(N=C(N=C2)NC2=NC=C(C=C2)CN2CCNCC2)N(C1=O)[C@@H]1CN(CCC1)C(CC)=O)C Chemical compound ClC1=C(C=CC=C1)C1=C(C2=C(N=C(N=C2)NC2=NC=C(C=C2)CN2CCNCC2)N(C1=O)[C@@H]1CN(CCC1)C(CC)=O)C XNBXJQDCLBLGOC-QHCPKHFHSA-N 0.000 claims description 5
- TUTIGZDLASTGET-MHZLTWQESA-N ClC=1C=C(C=CC=1)C1=C(C2=C(N=C(N=C2)NC2=CC(=C(C=C2)N2CCN(CC2)C)C)N(C1=O)[C@@H]1CN(CCC1)C(CC)=O)C Chemical compound ClC=1C=C(C=CC=1)C1=C(C2=C(N=C(N=C2)NC2=CC(=C(C=C2)N2CCN(CC2)C)C)N(C1=O)[C@@H]1CN(CCC1)C(CC)=O)C TUTIGZDLASTGET-MHZLTWQESA-N 0.000 claims description 5
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 5
- 206010060862 Prostate cancer Diseases 0.000 claims description 5
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 5
- 125000000217 alkyl group Chemical group 0.000 claims description 5
- 239000011737 fluorine Substances 0.000 claims description 5
- 125000002883 imidazolyl group Chemical group 0.000 claims description 5
- 201000005202 lung cancer Diseases 0.000 claims description 5
- 208000020816 lung neoplasm Diseases 0.000 claims description 5
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 5
- 150000003672 ureas Chemical class 0.000 claims description 5
- PKDPUENCROCRCH-UHFFFAOYSA-N 1-piperazin-1-ylethanone Chemical compound CC(=O)N1CCNCC1 PKDPUENCROCRCH-UHFFFAOYSA-N 0.000 claims description 4
- LPEPGSBLIPVRLB-UHFFFAOYSA-N C(C)(=O)N1CCC(CC1)N1C(C(=CC2=C1N=C(N=C2)NC1=CC(=C(C=C1)N1CCN(CC1)C)C)C1=C(C=CC=C1)Cl)=O Chemical compound C(C)(=O)N1CCC(CC1)N1C(C(=CC2=C1N=C(N=C2)NC1=CC(=C(C=C1)N1CCN(CC1)C)C)C1=C(C=CC=C1)Cl)=O LPEPGSBLIPVRLB-UHFFFAOYSA-N 0.000 claims description 4
- SVYXIZOQINCVST-UHFFFAOYSA-N C1(CCCC1)N1C(C(=C(C2=C1N=C(N=C2)NC1=CC(=C(C=C1)N1CCN(CC1)C)C)C)C1=CC=CC=C1)=O Chemical compound C1(CCCC1)N1C(C(=C(C2=C1N=C(N=C2)NC1=CC(=C(C=C1)N1CCN(CC1)C)C)C)C1=CC=CC=C1)=O SVYXIZOQINCVST-UHFFFAOYSA-N 0.000 claims description 4
- SQAFRJXKHNXNJB-UHFFFAOYSA-N C1(CCCCC1)N1C(C(=C(C2=C1N=C(N=C2)NC1=CC(=C(C=C1)N1CCN(CC1)C)C)C)C1=CC=CC=C1)=O Chemical compound C1(CCCCC1)N1C(C(=C(C2=C1N=C(N=C2)NC1=CC(=C(C=C1)N1CCN(CC1)C)C)C)C1=CC=CC=C1)=O SQAFRJXKHNXNJB-UHFFFAOYSA-N 0.000 claims description 4
- UFGMTIHPRKPZNV-UHFFFAOYSA-N ClC1=C(C=CC=C1)C1=C(C2=C(N=C(N=C2)NC2=CC(=C(C=C2)N2CCN(CC2)C)C)N(C1=O)C1CCN(CC1)C(CC)=O)C Chemical compound ClC1=C(C=CC=C1)C1=C(C2=C(N=C(N=C2)NC2=CC(=C(C=C2)N2CCN(CC2)C)C)N(C1=O)C1CCN(CC1)C(CC)=O)C UFGMTIHPRKPZNV-UHFFFAOYSA-N 0.000 claims description 4
- JBPVUCPENKTTNX-UHFFFAOYSA-N ClC1=C(C=CC=C1)C1=CC2=C(N=C(N=C2)NC2=CC(=C(C=C2)N2CCN(CC2)C)C)N(C1=O)C1CCCCC1 Chemical compound ClC1=C(C=CC=C1)C1=CC2=C(N=C(N=C2)NC2=CC(=C(C=C2)N2CCN(CC2)C)C)N(C1=O)C1CCCCC1 JBPVUCPENKTTNX-UHFFFAOYSA-N 0.000 claims description 4
- MBRQVOWPFZPXOF-UHFFFAOYSA-N ClC1=C(C=CC=C1)C1=CC2=C(N=C(N=C2)NC2=CC(=C(C=C2)N2CCN(CC2)C)C)N(C1=O)C1CCN(CC1)C(CC)=O Chemical compound ClC1=C(C=CC=C1)C1=CC2=C(N=C(N=C2)NC2=CC(=C(C=C2)N2CCN(CC2)C)C)N(C1=O)C1CCN(CC1)C(CC)=O MBRQVOWPFZPXOF-UHFFFAOYSA-N 0.000 claims description 4
- 206010061306 Nasopharyngeal cancer Diseases 0.000 claims description 4
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 4
- 125000002837 carbocyclic group Chemical group 0.000 claims description 4
- RHJVIGLEIFVHIJ-UHFFFAOYSA-N cyclohexanecarboxamide Chemical compound NC(=O)C1[CH]CCCC1 RHJVIGLEIFVHIJ-UHFFFAOYSA-N 0.000 claims description 4
- OJEYDZBIAYMFFD-UHFFFAOYSA-N cyclopentanecarboxamide Chemical compound NC(=O)C1C[CH]CC1 OJEYDZBIAYMFFD-UHFFFAOYSA-N 0.000 claims description 4
- BSEXNZMHLUMQKR-UHFFFAOYSA-N cyclopropanecarboxamide Chemical compound NC(=O)C1CC1.NC(=O)C1CC1 BSEXNZMHLUMQKR-UHFFFAOYSA-N 0.000 claims description 4
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims description 4
- 208000032839 leukemia Diseases 0.000 claims description 4
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 4
- 201000002528 pancreatic cancer Diseases 0.000 claims description 4
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 4
- HLEKYJVHEBHTMR-UHFFFAOYSA-N pentanamide Chemical compound CCCCC(N)=O.CCCCC(N)=O HLEKYJVHEBHTMR-UHFFFAOYSA-N 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- XIPFMBOWZXULIA-UHFFFAOYSA-N pivalamide Chemical compound CC(C)(C)C(N)=O XIPFMBOWZXULIA-UHFFFAOYSA-N 0.000 claims description 4
- 125000003003 spiro group Chemical group 0.000 claims description 4
- OGBHCPNYOJPJEW-UHFFFAOYSA-N 1-ethyl-4-(2-methylphenyl)piperazine Chemical compound C1CN(CC)CCN1C1=CC=CC=C1C OGBHCPNYOJPJEW-UHFFFAOYSA-N 0.000 claims description 3
- WQDDXVGJRSTLED-UHFFFAOYSA-N 1-methyl-4-phenylpiperazine Chemical compound C1CN(C)CCN1C1=CC=CC=C1 WQDDXVGJRSTLED-UHFFFAOYSA-N 0.000 claims description 3
- 125000004575 3-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 3
- 206010005003 Bladder cancer Diseases 0.000 claims description 3
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 3
- LDHPJCCCJKDEKE-QHCPKHFHSA-N ClC1=C(C=CC=C1)C1=C(C2=C(N=C(N=C2)NC2=NC=C(C=C2)N2CCN(CC2)C)N(C1=O)[C@@H]1CN(CCC1)C(CC)=O)C Chemical compound ClC1=C(C=CC=C1)C1=C(C2=C(N=C(N=C2)NC2=NC=C(C=C2)N2CCN(CC2)C)N(C1=O)[C@@H]1CN(CCC1)C(CC)=O)C LDHPJCCCJKDEKE-QHCPKHFHSA-N 0.000 claims description 3
- 206010009944 Colon cancer Diseases 0.000 claims description 3
- PMPVIKIVABFJJI-UHFFFAOYSA-N Cyclobutane Chemical compound C1CCC1 PMPVIKIVABFJJI-UHFFFAOYSA-N 0.000 claims description 3
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 3
- 206010023825 Laryngeal cancer Diseases 0.000 claims description 3
- 206010025323 Lymphomas Diseases 0.000 claims description 3
- 208000034578 Multiple myelomas Diseases 0.000 claims description 3
- 206010033128 Ovarian cancer Diseases 0.000 claims description 3
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 3
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 3
- 208000015634 Rectal Neoplasms Diseases 0.000 claims description 3
- 206010038389 Renal cancer Diseases 0.000 claims description 3
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 3
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 3
- 239000004480 active ingredient Substances 0.000 claims description 3
- 125000006615 aromatic heterocyclic group Chemical group 0.000 claims description 3
- 229910052794 bromium Inorganic materials 0.000 claims description 3
- 201000010881 cervical cancer Diseases 0.000 claims description 3
- 208000029742 colonic neoplasm Diseases 0.000 claims description 3
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 claims description 3
- RWTNPBWLLIMQHL-UHFFFAOYSA-N fexofenadine Chemical group C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RWTNPBWLLIMQHL-UHFFFAOYSA-N 0.000 claims description 3
- 201000010982 kidney cancer Diseases 0.000 claims description 3
- 206010023841 laryngeal neoplasm Diseases 0.000 claims description 3
- 201000001441 melanoma Diseases 0.000 claims description 3
- 125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 claims description 3
- UDJFFSGCRRMVFH-UHFFFAOYSA-N pyrido[2,3-d]pyrimidine Chemical compound N1=CN=CC2=CC=CN=C21 UDJFFSGCRRMVFH-UHFFFAOYSA-N 0.000 claims description 3
- 206010038038 rectal cancer Diseases 0.000 claims description 3
- 201000001275 rectum cancer Diseases 0.000 claims description 3
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 3
- 125000006527 (C1-C5) alkyl group Chemical group 0.000 claims description 2
- 125000002733 (C1-C6) fluoroalkyl group Chemical group 0.000 claims description 2
- AOYSLJHKVBSXRU-UHFFFAOYSA-N 1-(oxetan-3-yl)piperazine Chemical compound C1OCC1N1CCNCC1 AOYSLJHKVBSXRU-UHFFFAOYSA-N 0.000 claims description 2
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims description 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 2
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 2
- 125000004193 piperazinyl group Chemical group 0.000 claims description 2
- 125000003554 tetrahydropyrrolyl group Chemical group 0.000 claims description 2
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 5
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 claims 3
- 101150039808 Egfr gene Proteins 0.000 claims 1
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 claims 1
- XZOWIJDBQIHMFC-UHFFFAOYSA-N butanamide Chemical compound CCCC(N)=O.CCCC(N)=O XZOWIJDBQIHMFC-UHFFFAOYSA-N 0.000 claims 1
- 108700021358 erbB-1 Genes Proteins 0.000 claims 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims 1
- 229960005181 morphine Drugs 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 12
- 239000003112 inhibitor Substances 0.000 abstract description 10
- DUYJMQONPNNFPI-UHFFFAOYSA-N osimertinib Chemical compound COC1=CC(N(C)CCN(C)C)=C(NC(=O)C=C)C=C1NC1=NC=CC(C=2C3=CC=CC=C3N(C)C=2)=N1 DUYJMQONPNNFPI-UHFFFAOYSA-N 0.000 abstract description 7
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 abstract description 6
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 abstract description 5
- 235000018417 cysteine Nutrition 0.000 abstract description 5
- 210000004881 tumor cell Anatomy 0.000 abstract description 5
- HUFOZJXAKZVRNJ-UHFFFAOYSA-N n-[3-[[2-[4-(4-acetylpiperazin-1-yl)-2-methoxyanilino]-5-(trifluoromethyl)pyrimidin-4-yl]amino]phenyl]prop-2-enamide Chemical compound COC1=CC(N2CCN(CC2)C(C)=O)=CC=C1NC(N=1)=NC=C(C(F)(F)F)C=1NC1=CC=CC(NC(=O)C=C)=C1 HUFOZJXAKZVRNJ-UHFFFAOYSA-N 0.000 abstract description 4
- 229950009855 rociletinib Drugs 0.000 abstract description 4
- 239000002246 antineoplastic agent Substances 0.000 abstract description 2
- 229940041181 antineoplastic drug Drugs 0.000 abstract description 2
- 239000003560 cancer drug Substances 0.000 abstract description 2
- 230000012010 growth Effects 0.000 abstract description 2
- FDMQDKQUTRLUBU-UHFFFAOYSA-N n-[3-[2-[4-(4-methylpiperazin-1-yl)anilino]thieno[3,2-d]pyrimidin-4-yl]oxyphenyl]prop-2-enamide Chemical compound C1CN(C)CCN1C(C=C1)=CC=C1NC1=NC(OC=2C=C(NC(=O)C=C)C=CC=2)=C(SC=C2)C2=N1 FDMQDKQUTRLUBU-UHFFFAOYSA-N 0.000 abstract description 2
- 229950000778 olmutinib Drugs 0.000 abstract description 2
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 abstract 4
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 abstract 4
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 abstract 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 276
- 238000005481 NMR spectroscopy Methods 0.000 description 144
- 238000001308 synthesis method Methods 0.000 description 71
- 230000015572 biosynthetic process Effects 0.000 description 63
- 238000003786 synthesis reaction Methods 0.000 description 62
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 55
- 102000001301 EGF receptor Human genes 0.000 description 52
- 108060006698 EGF receptor Proteins 0.000 description 52
- 102200048955 rs121434569 Human genes 0.000 description 24
- 229940079593 drug Drugs 0.000 description 23
- 210000004027 cell Anatomy 0.000 description 22
- 239000000243 solution Substances 0.000 description 21
- 239000011734 sodium Substances 0.000 description 19
- 238000006243 chemical reaction Methods 0.000 description 18
- 239000012074 organic phase Substances 0.000 description 16
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 14
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 10
- 238000003756 stirring Methods 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 8
- 229940024606 amino acid Drugs 0.000 description 8
- 235000001014 amino acid Nutrition 0.000 description 8
- 150000001413 amino acids Chemical class 0.000 description 8
- 238000004440 column chromatography Methods 0.000 description 8
- 230000005764 inhibitory process Effects 0.000 description 8
- 239000007787 solid Substances 0.000 description 8
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 7
- 229910004298 SiO 2 Inorganic materials 0.000 description 7
- 239000002585 base Substances 0.000 description 7
- 125000001072 heteroaryl group Chemical group 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 238000011282 treatment Methods 0.000 description 7
- 0 C*[C@]1CN(C)CCC1 Chemical compound C*[C@]1CN(C)CCC1 0.000 description 6
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 230000026731 phosphorylation Effects 0.000 description 6
- 238000006366 phosphorylation reaction Methods 0.000 description 6
- 229940121649 protein inhibitor Drugs 0.000 description 6
- 239000012268 protein inhibitor Substances 0.000 description 6
- LFKDJXLFVYVEFG-UHFFFAOYSA-N tert-butyl carbamate Chemical compound CC(C)(C)OC(N)=O LFKDJXLFVYVEFG-UHFFFAOYSA-N 0.000 description 6
- ZBDWHKYIBYEOLF-VWLOTQADSA-N C(C)(C)(C)OC(=O)N1C[C@H](CC1)N1C(C(=CC2=C1N=C(N=C2)NC1=CC(=C(C=C1)N1CCN(CC1)C)C)C1=C(C=CC=C1)Cl)=O Chemical compound C(C)(C)(C)OC(=O)N1C[C@H](CC1)N1C(C(=CC2=C1N=C(N=C2)NC1=CC(=C(C=C1)N1CCN(CC1)C)C)C1=C(C=CC=C1)Cl)=O ZBDWHKYIBYEOLF-VWLOTQADSA-N 0.000 description 5
- RKUWLURYUSBGHO-HNNXBMFYSA-N C(C)(C)(C)OC(=O)N1C[C@H](CC1)N1C(C(=CC2=C1N=C(N=C2)S(=O)(=O)C)C1=C(C=CC=C1)Cl)=O Chemical compound C(C)(C)(C)OC(=O)N1C[C@H](CC1)N1C(C(=CC2=C1N=C(N=C2)S(=O)(=O)C)C1=C(C=CC=C1)Cl)=O RKUWLURYUSBGHO-HNNXBMFYSA-N 0.000 description 5
- QKGCUYLYSMYLHK-QFIPXVFZSA-N ClC1=C(C=CC=C1)C1=CC2=C(N=C(N=C2)NC2=CC(=C(C=C2)N2CCN(CC2)C)C)N(C1=O)[C@@H]1CNCC1 Chemical compound ClC1=C(C=CC=C1)C1=CC2=C(N=C(N=C2)NC2=CC(=C(C=C2)N2CCN(CC2)C)C)N(C1=O)[C@@H]1CNCC1 QKGCUYLYSMYLHK-QFIPXVFZSA-N 0.000 description 5
- 102000014150 Interferons Human genes 0.000 description 5
- 108010050904 Interferons Proteins 0.000 description 5
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 5
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 5
- 108091000080 Phosphotransferase Proteins 0.000 description 5
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 5
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 229940079322 interferon Drugs 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 102000020233 phosphotransferase Human genes 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 239000007858 starting material Substances 0.000 description 5
- 230000004083 survival effect Effects 0.000 description 5
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 4
- SIKXIUWKPGWBBF-UHFFFAOYSA-N 5-bromo-2,4-dichloropyrimidine Chemical compound ClC1=NC=C(Br)C(Cl)=N1 SIKXIUWKPGWBBF-UHFFFAOYSA-N 0.000 description 4
- VODHPEVDTUVVAT-HNNXBMFYSA-N C(C)(C)(C)OC(=O)N1C[C@H](CC1)N1C(C(=CC2=C1N=C(N=C2)SC)C1=C(C=CC=C1)Cl)=O Chemical compound C(C)(C)(C)OC(=O)N1C[C@H](CC1)N1C(C(=CC2=C1N=C(N=C2)SC)C1=C(C=CC=C1)Cl)=O VODHPEVDTUVVAT-HNNXBMFYSA-N 0.000 description 4
- 206010059866 Drug resistance Diseases 0.000 description 4
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 4
- 239000005551 L01XE03 - Erlotinib Substances 0.000 description 4
- 229920001213 Polysorbate 20 Polymers 0.000 description 4
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 4
- 239000004473 Threonine Substances 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- BTANRVKWQNVYAZ-UHFFFAOYSA-N butan-2-ol Chemical compound CCC(C)O BTANRVKWQNVYAZ-UHFFFAOYSA-N 0.000 description 4
- 125000004432 carbon atom Chemical group C* 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- 238000010828 elution Methods 0.000 description 4
- 229960001433 erlotinib Drugs 0.000 description 4
- 238000002866 fluorescence resonance energy transfer Methods 0.000 description 4
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 4
- 150000002431 hydrogen Chemical class 0.000 description 4
- 231100000682 maximum tolerated dose Toxicity 0.000 description 4
- XBXCNNQPRYLIDE-UHFFFAOYSA-M n-tert-butylcarbamate Chemical compound CC(C)(C)NC([O-])=O XBXCNNQPRYLIDE-UHFFFAOYSA-M 0.000 description 4
- 231100000252 nontoxic Toxicity 0.000 description 4
- 230000003000 nontoxic effect Effects 0.000 description 4
- 229960003278 osimertinib Drugs 0.000 description 4
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 4
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 125000004076 pyridyl group Chemical group 0.000 description 4
- 238000002626 targeted therapy Methods 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 238000005160 1H NMR spectroscopy Methods 0.000 description 3
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 3
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 description 3
- 108010029961 Filgrastim Proteins 0.000 description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
- 108010047761 Interferon-alpha Proteins 0.000 description 3
- 102000006992 Interferon-alpha Human genes 0.000 description 3
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 3
- 239000005411 L01XE02 - Gefitinib Substances 0.000 description 3
- 208000002454 Nasopharyngeal Carcinoma Diseases 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 229930012538 Paclitaxel Natural products 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 125000002619 bicyclic group Chemical group 0.000 description 3
- DNSISZSEWVHGLH-UHFFFAOYSA-N butanamide Chemical compound CCCC(N)=O DNSISZSEWVHGLH-UHFFFAOYSA-N 0.000 description 3
- 150000001721 carbon Chemical group 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 229960005309 estradiol Drugs 0.000 description 3
- 235000019439 ethyl acetate Nutrition 0.000 description 3
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 3
- YLMAHDNUQAMNNX-UHFFFAOYSA-N imatinib methanesulfonate Chemical compound CS(O)(=O)=O.C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 YLMAHDNUQAMNNX-UHFFFAOYSA-N 0.000 description 3
- 150000007529 inorganic bases Chemical class 0.000 description 3
- GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 description 3
- 229960004338 leuprorelin Drugs 0.000 description 3
- 229960003918 levothyroxine sodium Drugs 0.000 description 3
- YDTFRJLNMPSCFM-YDALLXLXSA-M levothyroxine sodium anhydrous Chemical compound [Na+].IC1=CC(C[C@H](N)C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 YDTFRJLNMPSCFM-YDALLXLXSA-M 0.000 description 3
- SXQCTESRRZBPHJ-UHFFFAOYSA-M lissamine rhodamine Chemical compound [Na+].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=C(S([O-])(=O)=O)C=C1S([O-])(=O)=O SXQCTESRRZBPHJ-UHFFFAOYSA-M 0.000 description 3
- 229930182817 methionine Natural products 0.000 description 3
- 150000007522 mineralic acids Chemical class 0.000 description 3
- 201000011216 nasopharynx carcinoma Diseases 0.000 description 3
- 150000007524 organic acids Chemical class 0.000 description 3
- 125000002971 oxazolyl group Chemical group 0.000 description 3
- 229960001592 paclitaxel Drugs 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 238000002390 rotary evaporation Methods 0.000 description 3
- 150000003384 small molecules Chemical class 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 229960003787 sorafenib Drugs 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 229960001603 tamoxifen Drugs 0.000 description 3
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 3
- 125000001544 thienyl group Chemical group 0.000 description 3
- 125000001425 triazolyl group Chemical group 0.000 description 3
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
- DEQANNDTNATYII-OULOTJBUSA-N (4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-19-[[(2r)-2-amino-3-phenylpropanoyl]amino]-16-benzyl-n-[(2r,3r)-1,3-dihydroxybutan-2-yl]-7-[(1r)-1-hydroxyethyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxa Chemical compound C([C@@H](N)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC=2C3=CC=CC=C3NC=2)NC(=O)[C@H](CC=2C=CC=CC=2)NC1=O)C(=O)N[C@H](CO)[C@H](O)C)C1=CC=CC=C1 DEQANNDTNATYII-OULOTJBUSA-N 0.000 description 2
- OJFSCKNLUYOABN-UHFFFAOYSA-N 1h-1,5-naphthyridin-2-one Chemical class N1=CC=CC2=NC(O)=CC=C21 OJFSCKNLUYOABN-UHFFFAOYSA-N 0.000 description 2
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 2
- OGWKCGZFUXNPDA-CFWMRBGOSA-N 5j49q6b70f Chemical compound C([C@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C=O)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 OGWKCGZFUXNPDA-CFWMRBGOSA-N 0.000 description 2
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 2
- 229930024421 Adenine Natural products 0.000 description 2
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- 239000005711 Benzoic acid Substances 0.000 description 2
- WTZWOPISXJAPOR-VWLOTQADSA-N C(C)(=O)N1C[C@H](CCC1)N1C(C(=C(C2=C1N=C(N=C2)NC1=CC(=C(C=C1)N1CCN(CC1)C)C)C)C1=C(C=C(C=C1)F)Cl)=O Chemical compound C(C)(=O)N1C[C@H](CCC1)N1C(C(=C(C2=C1N=C(N=C2)NC1=CC(=C(C=C1)N1CCN(CC1)C)C)C)C1=C(C=C(C=C1)F)Cl)=O WTZWOPISXJAPOR-VWLOTQADSA-N 0.000 description 2
- IDFCVNXSTLJXPT-NSHDSACASA-N C(C)(C)(C)OC(=O)N1C[C@H](CC1)NC1=NC(=NC=C1CO)SC Chemical compound C(C)(C)(C)OC(=O)N1C[C@H](CC1)NC1=NC(=NC=C1CO)SC IDFCVNXSTLJXPT-NSHDSACASA-N 0.000 description 2
- IWUQOYKCIWQLQI-VWLOTQADSA-N ClC1=C(C=CC(=C1)F)C1=C(C2=C(N=C(N=C2)NC2=CC(=C(C=C2)N2CCN(CC2)C)C)N(C1=O)[C@@H]1CN(CCC1)C(CC)=O)C Chemical compound ClC1=C(C=CC(=C1)F)C1=C(C2=C(N=C(N=C2)NC2=CC(=C(C=C2)N2CCN(CC2)C)C)N(C1=O)[C@@H]1CN(CCC1)C(CC)=O)C IWUQOYKCIWQLQI-VWLOTQADSA-N 0.000 description 2
- GOBZRBXLYLWGPS-SANMLTNESA-N ClC1=C(C=CC=C1)C1=C(C2=C(N=C(N=C2)NC2=C(C=C(C(=C2)C)C2CCNCC2)OC(C)C)N(C1=O)[C@@H]1CN(CCC1)C(CC)=O)C Chemical compound ClC1=C(C=CC=C1)C1=C(C2=C(N=C(N=C2)NC2=C(C=C(C(=C2)C)C2CCNCC2)OC(C)C)N(C1=O)[C@@H]1CN(CCC1)C(CC)=O)C GOBZRBXLYLWGPS-SANMLTNESA-N 0.000 description 2
- PKKKHPQPUNNGPA-VWLOTQADSA-N ClC1=C(C=CC=C1)C1=C(C2=C(N=C(N=C2)NC2=CC(=C(C=C2)C2CCNCC2)C)N(C1=O)[C@@H]1CN(CCC1)C(CC)=O)C Chemical compound ClC1=C(C=CC=C1)C1=C(C2=C(N=C(N=C2)NC2=CC(=C(C=C2)C2CCNCC2)C)N(C1=O)[C@@H]1CN(CCC1)C(CC)=O)C PKKKHPQPUNNGPA-VWLOTQADSA-N 0.000 description 2
- KXANCNBGQKSENS-SANMLTNESA-N ClC1=C(C=CC=C1)C1=C(C2=C(N=C(N=C2)NC2=CC(=C(C=C2)N2CCN(CC2)CC)C)N(C1=O)[C@@H]1CN(CCC1)C(CC)=O)C Chemical compound ClC1=C(C=CC=C1)C1=C(C2=C(N=C(N=C2)NC2=CC(=C(C=C2)N2CCN(CC2)CC)C)N(C1=O)[C@@H]1CN(CCC1)C(CC)=O)C KXANCNBGQKSENS-SANMLTNESA-N 0.000 description 2
- YCNFPFJTZKKJRM-DEOSSOPVSA-N ClC1=C(C=CC=C1)C1=C(C2=C(N=C(N=C2)NC2=NC=C(C=C2)CN2CCN(CC2)C)N(C1=O)[C@@H]1CN(CCC1)C(CC)=O)C Chemical compound ClC1=C(C=CC=C1)C1=C(C2=C(N=C(N=C2)NC2=NC=C(C=C2)CN2CCN(CC2)C)N(C1=O)[C@@H]1CN(CCC1)C(CC)=O)C YCNFPFJTZKKJRM-DEOSSOPVSA-N 0.000 description 2
- FZOZLHYMVDEAHQ-UHFFFAOYSA-N ClC=1C=C(C=CC=1)C1=C(C2=C(N=C(N=C2)NC2=CC(=C(C=C2)N2CCN(CC2)C)C)N(C1=O)C1CCCCC1)C Chemical compound ClC=1C=C(C=CC=1)C1=C(C2=C(N=C(N=C2)NC2=CC(=C(C=C2)N2CCN(CC2)C)C)N(C1=O)C1CCCCC1)C FZOZLHYMVDEAHQ-UHFFFAOYSA-N 0.000 description 2
- KAHXJVRJUJORAA-DEOSSOPVSA-N ClC=1C=NC=CC=1C1=C(C2=C(N=C(N=C2)NC2=CC(=C(C=C2)N2CCN(CC2)C)C)N(C1=O)[C@@H]1CN(CCC1)C(CC)=O)C Chemical compound ClC=1C=NC=CC=1C1=C(C2=C(N=C(N=C2)NC2=CC(=C(C=C2)N2CCN(CC2)C)C)N(C1=O)[C@@H]1CN(CCC1)C(CC)=O)C KAHXJVRJUJORAA-DEOSSOPVSA-N 0.000 description 2
- PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- CYQFCXCEBYINGO-DLBZAZTESA-N Dronabinol Natural products C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@H]21 CYQFCXCEBYINGO-DLBZAZTESA-N 0.000 description 2
- 206010071975 EGFR gene mutation Diseases 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 102100039619 Granulocyte colony-stimulating factor Human genes 0.000 description 2
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 102000000588 Interleukin-2 Human genes 0.000 description 2
- 108010002350 Interleukin-2 Proteins 0.000 description 2
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 2
- 108010000817 Leuprolide Proteins 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 2
- 150000001204 N-oxides Chemical class 0.000 description 2
- 239000000020 Nitrocellulose Substances 0.000 description 2
- 108010016076 Octreotide Proteins 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- 102100033237 Pro-epidermal growth factor Human genes 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- CYQFCXCEBYINGO-UHFFFAOYSA-N THC Natural products C1=C(C)CCC2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3C21 CYQFCXCEBYINGO-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 2
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 2
- 229960000583 acetic acid Drugs 0.000 description 2
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 2
- 239000012346 acetyl chloride Substances 0.000 description 2
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 2
- 125000001931 aliphatic group Chemical group 0.000 description 2
- JKOQGQFVAUAYPM-UHFFFAOYSA-N amifostine Chemical compound NCCCNCCSP(O)(O)=O JKOQGQFVAUAYPM-UHFFFAOYSA-N 0.000 description 2
- 229960001097 amifostine Drugs 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 150000003863 ammonium salts Chemical class 0.000 description 2
- 230000003698 anagen phase Effects 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- 150000007514 bases Chemical class 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 159000000007 calcium salts Chemical class 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 229960002436 cladribine Drugs 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 230000000875 corresponding effect Effects 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 229960000975 daunorubicin Drugs 0.000 description 2
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 2
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 description 2
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 229960004242 dronabinol Drugs 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 229930182833 estradiol Natural products 0.000 description 2
- 229960004177 filgrastim Drugs 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 229960002584 gefitinib Drugs 0.000 description 2
- 229960002442 glucosamine Drugs 0.000 description 2
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 2
- 229960004198 guanidine Drugs 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- HHXHVIJIIXKSOE-QILQGKCVSA-N histrelin Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC(N=C1)=CN1CC1=CC=CC=C1 HHXHVIJIIXKSOE-QILQGKCVSA-N 0.000 description 2
- 108700020746 histrelin Proteins 0.000 description 2
- 229960002193 histrelin Drugs 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 2
- 229960003685 imatinib mesylate Drugs 0.000 description 2
- 239000013038 irreversible inhibitor Substances 0.000 description 2
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 2
- 125000000842 isoxazolyl group Chemical group 0.000 description 2
- 238000000021 kinase assay Methods 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 159000000003 magnesium salts Chemical class 0.000 description 2
- 150000002696 manganese Chemical class 0.000 description 2
- NUJOXMJBOLGQSY-UHFFFAOYSA-N manganese dioxide Chemical compound O=[Mn]=O NUJOXMJBOLGQSY-UHFFFAOYSA-N 0.000 description 2
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 2
- 229960000485 methotrexate Drugs 0.000 description 2
- 125000002950 monocyclic group Chemical group 0.000 description 2
- LBWFXVZLPYTWQI-IPOVEDGCSA-N n-[2-(diethylamino)ethyl]-5-[(z)-(5-fluoro-2-oxo-1h-indol-3-ylidene)methyl]-2,4-dimethyl-1h-pyrrole-3-carboxamide;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C LBWFXVZLPYTWQI-IPOVEDGCSA-N 0.000 description 2
- 229920001220 nitrocellulos Polymers 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 229960002700 octreotide Drugs 0.000 description 2
- 150000007530 organic bases Chemical class 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- PIBWKRNGBLPSSY-UHFFFAOYSA-L palladium(II) chloride Chemical compound Cl[Pd]Cl PIBWKRNGBLPSSY-UHFFFAOYSA-L 0.000 description 2
- CPJSUEIXXCENMM-UHFFFAOYSA-N phenacetin Chemical compound CCOC1=CC=C(NC(C)=O)C=C1 CPJSUEIXXCENMM-UHFFFAOYSA-N 0.000 description 2
- XUWHAWMETYGRKB-UHFFFAOYSA-N piperidin-2-one Chemical compound O=C1CCCCN1 XUWHAWMETYGRKB-UHFFFAOYSA-N 0.000 description 2
- 230000002980 postoperative effect Effects 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 159000000001 potassium salts Chemical class 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 125000003373 pyrazinyl group Chemical group 0.000 description 2
- 125000003226 pyrazolyl group Chemical group 0.000 description 2
- 125000002098 pyridazinyl group Chemical group 0.000 description 2
- 125000000714 pyrimidinyl group Chemical group 0.000 description 2
- 125000000168 pyrrolyl group Chemical group 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 159000000000 sodium salts Chemical class 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 229960002812 sunitinib malate Drugs 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- YAPQBXQYLJRXSA-UHFFFAOYSA-N theobromine Chemical compound CN1C(=O)NC(=O)C2=C1N=CN2C YAPQBXQYLJRXSA-UHFFFAOYSA-N 0.000 description 2
- XFCLJVABOIYOMF-QPLCGJKRSA-N toremifene Chemical compound C1=CC(OCCN(C)C)=CC=C1C(\C=1C=CC=CC=1)=C(\CCCl)C1=CC=CC=C1 XFCLJVABOIYOMF-QPLCGJKRSA-N 0.000 description 2
- 229960005026 toremifene Drugs 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- 229960000281 trometamol Drugs 0.000 description 2
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 2
- 229960003048 vinblastine Drugs 0.000 description 2
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 2
- QCHFTSOMWOSFHM-WPRPVWTQSA-N (+)-Pilocarpine Chemical compound C1OC(=O)[C@@H](CC)[C@H]1CC1=CN=CN1C QCHFTSOMWOSFHM-WPRPVWTQSA-N 0.000 description 1
- DNXHEGUUPJUMQT-UHFFFAOYSA-N (+)-estrone Natural products OC1=CC=C2C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 DNXHEGUUPJUMQT-UHFFFAOYSA-N 0.000 description 1
- VCGRFBXVSFAGGA-UHFFFAOYSA-N (1,1-dioxo-1,4-thiazinan-4-yl)-[6-[[3-(4-fluorophenyl)-5-methyl-1,2-oxazol-4-yl]methoxy]pyridin-3-yl]methanone Chemical compound CC=1ON=C(C=2C=CC(F)=CC=2)C=1COC(N=C1)=CC=C1C(=O)N1CCS(=O)(=O)CC1 VCGRFBXVSFAGGA-UHFFFAOYSA-N 0.000 description 1
- RRCMGJCFMJBHQC-UHFFFAOYSA-N (2-chlorophenyl)boronic acid Chemical compound OB(O)C1=CC=CC=C1Cl RRCMGJCFMJBHQC-UHFFFAOYSA-N 0.000 description 1
- VESKBLGTHHPZJF-QNWVGRARSA-N (2s)-2-amino-5-[[(2r)-2-amino-3-[2-[bis[bis(2-chloroethyl)amino]phosphoryloxy]ethylsulfonyl]propanoyl]-[(r)-carboxy(phenyl)methyl]amino]-5-oxopentanoic acid Chemical compound ClCCN(CCCl)P(=O)(N(CCCl)CCCl)OCCS(=O)(=O)C[C@H](N)C(=O)N(C(=O)CC[C@H](N)C(O)=O)[C@@H](C(O)=O)C1=CC=CC=C1 VESKBLGTHHPZJF-QNWVGRARSA-N 0.000 description 1
- KCEHUPIXDRDKQS-VKHMYHEASA-N (2s)-5-amino-2-hydrazinyl-5-oxopentanoic acid Chemical compound NN[C@H](C(O)=O)CCC(N)=O KCEHUPIXDRDKQS-VKHMYHEASA-N 0.000 description 1
- ZBVJFYPGLGEMIN-OYLNGHKZSA-N (2s)-n-[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2r)-1-[[(2s)-1-[[(2s)-1-[(2s)-2-[(2-amino-2-oxoethyl)carbamoyl]pyrrolidin-1-yl]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1h-indol-3-yl)-1-oxopropan-2-yl]amino]-3-( Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1.C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 ZBVJFYPGLGEMIN-OYLNGHKZSA-N 0.000 description 1
- LUEWUZLMQUOBSB-FSKGGBMCSA-N (2s,3s,4s,5s,6r)-2-[(2r,3s,4r,5r,6s)-6-[(2r,3s,4r,5s,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5s,6r)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@@H](O[C@@H]2[C@H](O[C@@H](OC3[C@H](O[C@@H](O)[C@@H](O)[C@H]3O)CO)[C@@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O LUEWUZLMQUOBSB-FSKGGBMCSA-N 0.000 description 1
- SWXOGPJRIDTIRL-DOUNNPEJSA-N (4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-n-[(2s)-1-amino-3-(1h-indol-3-yl)-1-oxopropan-2-yl]-19-[[(2r)-2-amino-3-phenylpropanoyl]amino]-16-[(4-hydroxyphenyl)methyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-7-propan-2-yl-1,2-dithia-5,8,11,14,17-pent Chemical compound C([C@H]1C(=O)N[C@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](N)CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(N)=O)=O)C(C)C)C1=CC=C(O)C=C1 SWXOGPJRIDTIRL-DOUNNPEJSA-N 0.000 description 1
- PUDHBTGHUJUUFI-SCTWWAJVSA-N (4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-n-[(2s,3r)-1-amino-3-hydroxy-1-oxobutan-2-yl]-19-[[(2r)-2-amino-3-naphthalen-2-ylpropanoyl]amino]-16-[(4-hydroxyphenyl)methyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-7-propan-2-yl-1,2-dithia-5,8,11,14,17-p Chemical compound C([C@H]1C(=O)N[C@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](N)CC=1C=C2C=CC=CC2=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(N)=O)=O)C(C)C)C1=CC=C(O)C=C1 PUDHBTGHUJUUFI-SCTWWAJVSA-N 0.000 description 1
- GGQPTOITOZXLBE-QXROXWLYSA-N (6s,8r,9s,10r,13s,14s,17s)-6-fluoro-17-hydroxy-10,13-dimethyl-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-3-one Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3C[C@H](F)C2=C1 GGQPTOITOZXLBE-QXROXWLYSA-N 0.000 description 1
- MWWSFMDVAYGXBV-FGBSZODSSA-N (7s,9s)-7-[(2r,4s,5r,6s)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7h-tetracene-5,12-dione;hydron;chloride Chemical compound Cl.O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 MWWSFMDVAYGXBV-FGBSZODSSA-N 0.000 description 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 1
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- UWYVPFMHMJIBHE-OWOJBTEDSA-N (e)-2-hydroxybut-2-enedioic acid Chemical compound OC(=O)\C=C(\O)C(O)=O UWYVPFMHMJIBHE-OWOJBTEDSA-N 0.000 description 1
- ZGMJYTYLTJFNCS-VQYXCCSOSA-N (e)-but-2-enedioic acid;1-[4-(2-hydroxy-3-quinolin-5-yloxypropyl)piperazin-1-yl]-2,2-diphenylethanone Chemical compound OC(=O)\C=C\C(O)=O.OC(=O)\C=C\C(O)=O.OC(=O)\C=C\C(O)=O.C=1C=CC2=NC=CC=C2C=1OCC(O)CN(CC1)CCN1C(=O)C(C=1C=CC=CC=1)C1=CC=CC=C1.C=1C=CC2=NC=CC=C2C=1OCC(O)CN(CC1)CCN1C(=O)C(C=1C=CC=CC=1)C1=CC=CC=C1 ZGMJYTYLTJFNCS-VQYXCCSOSA-N 0.000 description 1
- MOWXJLUYGFNTAL-DEOSSOPVSA-N (s)-[2-chloro-4-fluoro-5-(7-morpholin-4-ylquinazolin-4-yl)phenyl]-(6-methoxypyridazin-3-yl)methanol Chemical compound N1=NC(OC)=CC=C1[C@@H](O)C1=CC(C=2C3=CC=C(C=C3N=CN=2)N2CCOCC2)=C(F)C=C1Cl MOWXJLUYGFNTAL-DEOSSOPVSA-N 0.000 description 1
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- VIESAWGOYVNHLV-UHFFFAOYSA-N 1,3-dihydropyrrol-2-one Chemical compound O=C1CC=CN1 VIESAWGOYVNHLV-UHFFFAOYSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- HJTAZXHBEBIQQX-UHFFFAOYSA-N 1,5-bis(chloromethyl)naphthalene Chemical compound C1=CC=C2C(CCl)=CC=CC2=C1CCl HJTAZXHBEBIQQX-UHFFFAOYSA-N 0.000 description 1
- ABDDQTDRAHXHOC-QMMMGPOBSA-N 1-[(7s)-5,7-dihydro-4h-thieno[2,3-c]pyran-7-yl]-n-methylmethanamine Chemical compound CNC[C@@H]1OCCC2=C1SC=C2 ABDDQTDRAHXHOC-QMMMGPOBSA-N 0.000 description 1
- VSNHCAURESNICA-NJFSPNSNSA-N 1-oxidanylurea Chemical compound N[14C](=O)NO VSNHCAURESNICA-NJFSPNSNSA-N 0.000 description 1
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 1
- BFPYWIDHMRZLRN-UHFFFAOYSA-N 17alpha-ethynyl estradiol Natural products OC1=CC=C2C3CCC(C)(C(CC4)(O)C#C)C4C3CCC2=C1 BFPYWIDHMRZLRN-UHFFFAOYSA-N 0.000 description 1
- GCKMFJBGXUYNAG-UHFFFAOYSA-N 17alpha-methyltestosterone Natural products C1CC2=CC(=O)CCC2(C)C2C1C1CCC(C)(O)C1(C)CC2 GCKMFJBGXUYNAG-UHFFFAOYSA-N 0.000 description 1
- KAESVJOAVNADME-UHFFFAOYSA-N 1H-pyrrole Natural products C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 1
- QMVPQBFHUJZJCS-NTKFZFFISA-N 1v8x590xdp Chemical compound O=C1N(NC(CO)CO)C(=O)C(C2=C3[CH]C=C(O)C=C3NC2=C23)=C1C2=C1C=CC(O)=C[C]1N3[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O QMVPQBFHUJZJCS-NTKFZFFISA-N 0.000 description 1
- NEBPTMCRLHKPOB-UHFFFAOYSA-N 2,2-diphenylacetonitrile Chemical compound C=1C=CC=CC=1C(C#N)C1=CC=CC=C1 NEBPTMCRLHKPOB-UHFFFAOYSA-N 0.000 description 1
- ROZCIVXTLACYNY-UHFFFAOYSA-N 2,3,4,5,6-pentafluoro-n-(3-fluoro-4-methoxyphenyl)benzenesulfonamide Chemical compound C1=C(F)C(OC)=CC=C1NS(=O)(=O)C1=C(F)C(F)=C(F)C(F)=C1F ROZCIVXTLACYNY-UHFFFAOYSA-N 0.000 description 1
- MOMFXATYAINJML-UHFFFAOYSA-N 2-Acetylthiazole Chemical group CC(=O)C1=NC=CS1 MOMFXATYAINJML-UHFFFAOYSA-N 0.000 description 1
- IXQGCWUGDFDQMF-UHFFFAOYSA-N 2-Ethylphenol Chemical compound CCC1=CC=CC=C1O IXQGCWUGDFDQMF-UHFFFAOYSA-N 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-Methylbenzenesulfonic acid Chemical compound CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 description 1
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- 229940013085 2-diethylaminoethanol Drugs 0.000 description 1
- LGEXGKUJMFHVSY-UHFFFAOYSA-N 2-n,4-n,6-n-trimethyl-1,3,5-triazine-2,4,6-triamine Chemical compound CNC1=NC(NC)=NC(NC)=N1 LGEXGKUJMFHVSY-UHFFFAOYSA-N 0.000 description 1
- WLJVXDMOQOGPHL-PPJXEINESA-N 2-phenylacetic acid Chemical compound O[14C](=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-PPJXEINESA-N 0.000 description 1
- HCDMJFOHIXMBOV-UHFFFAOYSA-N 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholin-4-ylmethyl)-4,7-dihydropyrrolo[4,5]pyrido[1,2-d]pyrimidin-2-one Chemical compound C=1C2=C3N(CC)C(=O)N(C=4C(=C(OC)C=C(OC)C=4F)F)CC3=CN=C2NC=1CN1CCOCC1 HCDMJFOHIXMBOV-UHFFFAOYSA-N 0.000 description 1
- WNEODWDFDXWOLU-QHCPKHFHSA-N 3-[3-(hydroxymethyl)-4-[1-methyl-5-[[5-[(2s)-2-methyl-4-(oxetan-3-yl)piperazin-1-yl]pyridin-2-yl]amino]-6-oxopyridin-3-yl]pyridin-2-yl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one Chemical compound C([C@@H](N(CC1)C=2C=NC(NC=3C(N(C)C=C(C=3)C=3C(=C(N4C(C5=CC=6CC(C)(C)CC=6N5CC4)=O)N=CC=3)CO)=O)=CC=2)C)N1C1COC1 WNEODWDFDXWOLU-QHCPKHFHSA-N 0.000 description 1
- WUIABRMSWOKTOF-OYALTWQYSA-N 3-[[2-[2-[2-[[(2s,3r)-2-[[(2s,3s,4r)-4-[[(2s,3r)-2-[[6-amino-2-[(1s)-3-amino-1-[[(2s)-2,3-diamino-3-oxopropyl]amino]-3-oxopropyl]-5-methylpyrimidine-4-carbonyl]amino]-3-[(2r,3s,4s,5s,6s)-3-[(2r,3s,4s,5r,6r)-4-carbamoyloxy-3,5-dihydroxy-6-(hydroxymethyl)ox Chemical compound OS([O-])(=O)=O.N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1NC=NC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C WUIABRMSWOKTOF-OYALTWQYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- CLPFFLWZZBQMAO-UHFFFAOYSA-N 4-(5,6,7,8-tetrahydroimidazo[1,5-a]pyridin-5-yl)benzonitrile Chemical compound C1=CC(C#N)=CC=C1C1N2C=NC=C2CCC1 CLPFFLWZZBQMAO-UHFFFAOYSA-N 0.000 description 1
- AKJHMTWEGVYYSE-AIRMAKDCSA-N 4-HPR Chemical compound C=1C=C(O)C=CC=1NC(=O)/C=C(\C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C AKJHMTWEGVYYSE-AIRMAKDCSA-N 0.000 description 1
- KVCQTKNUUQOELD-UHFFFAOYSA-N 4-amino-n-[1-(3-chloro-2-fluoroanilino)-6-methylisoquinolin-5-yl]thieno[3,2-d]pyrimidine-7-carboxamide Chemical compound N=1C=CC2=C(NC(=O)C=3C4=NC=NC(N)=C4SC=3)C(C)=CC=C2C=1NC1=CC=CC(Cl)=C1F KVCQTKNUUQOELD-UHFFFAOYSA-N 0.000 description 1
- HVBSAKJJOYLTQU-UHFFFAOYSA-N 4-aminobenzenesulfonic acid Chemical compound NC1=CC=C(S(O)(=O)=O)C=C1 HVBSAKJJOYLTQU-UHFFFAOYSA-N 0.000 description 1
- HVCNXQOWACZAFN-UHFFFAOYSA-N 4-ethylmorpholine Chemical compound CCN1CCOCC1 HVCNXQOWACZAFN-UHFFFAOYSA-N 0.000 description 1
- NMUSYJAQQFHJEW-UHFFFAOYSA-N 5-Azacytidine Natural products O=C1N=C(N)N=CN1C1C(O)C(O)C(CO)O1 NMUSYJAQQFHJEW-UHFFFAOYSA-N 0.000 description 1
- XAUDJQYHKZQPEU-KVQBGUIXSA-N 5-aza-2'-deoxycytidine Chemical compound O=C1N=C(N)N=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 XAUDJQYHKZQPEU-KVQBGUIXSA-N 0.000 description 1
- NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 description 1
- HFEKDTCAMMOLQP-RRKCRQDMSA-N 5-fluorodeoxyuridine monophosphate Chemical compound O1[C@H](COP(O)(O)=O)[C@@H](O)C[C@@H]1N1C(=O)NC(=O)C(F)=C1 HFEKDTCAMMOLQP-RRKCRQDMSA-N 0.000 description 1
- FHIDNBAQOFJWCA-UAKXSSHOSA-N 5-fluorouridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 FHIDNBAQOFJWCA-UAKXSSHOSA-N 0.000 description 1
- QMSWQUOSJSTBDR-XMMPIXPASA-N 6-(2-chlorophenyl)-5-methyl-2-[3-methyl-4-(4-methylpiperazin-1-yl)anilino]-8-[(3R)-1-propanoylpyrrolidin-3-yl]pyrido[2,3-d]pyrimidin-7-one Chemical compound ClC1=C(C=CC=C1)C1=C(C2=C(N=C(N=C2)NC2=CC(=C(C=C2)N2CCN(CC2)C)C)N(C1=O)[C@H]1CN(CC1)C(CC)=O)C QMSWQUOSJSTBDR-XMMPIXPASA-N 0.000 description 1
- FQWTWFPTHLTOLB-SANMLTNESA-N 6-(2-methoxyphenyl)-5-methyl-2-[3-methyl-4-(4-methylpiperazin-1-yl)anilino]-8-[(3S)-1-propanoylpiperidin-3-yl]pyrido[2,3-d]pyrimidin-7-one Chemical compound COC1=C(C=CC=C1)C1=C(C2=C(N=C(N=C2)NC2=CC(=C(C=C2)N2CCN(CC2)C)C)N(C1=O)[C@@H]1CN(CCC1)C(CC)=O)C FQWTWFPTHLTOLB-SANMLTNESA-N 0.000 description 1
- WYWHKKSPHMUBEB-UHFFFAOYSA-N 6-Mercaptoguanine Natural products N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 1
- VVIAGPKUTFNRDU-UHFFFAOYSA-N 6S-folinic acid Natural products C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-UHFFFAOYSA-N 0.000 description 1
- CYJRNFFLTBEQSQ-UHFFFAOYSA-N 8-(3-methyl-1-benzothiophen-5-yl)-N-(4-methylsulfonylpyridin-3-yl)quinoxalin-6-amine Chemical compound CS(=O)(=O)C1=C(C=NC=C1)NC=1C=C2N=CC=NC2=C(C=1)C=1C=CC2=C(C(=CS2)C)C=1 CYJRNFFLTBEQSQ-UHFFFAOYSA-N 0.000 description 1
- GFKGEQBUKQHHGE-XMMPIXPASA-N 8-[(3R)-1-acetylpyrrolidin-3-yl]-6-(2-chlorophenyl)-5-methyl-2-[3-methyl-4-(4-methylpiperazin-1-yl)anilino]pyrido[2,3-d]pyrimidin-7-one Chemical compound C(C)(=O)N1C[C@@H](CC1)N1C(C(=C(C2=C1N=C(N=C2)NC1=CC(=C(C=C1)N1CCN(CC1)C)C)C)C1=C(C=CC=C1)Cl)=O GFKGEQBUKQHHGE-XMMPIXPASA-N 0.000 description 1
- FYSKSIKODQJXSY-MHZLTWQESA-N 8-[(3S)-1-acetylpiperidin-3-yl]-5-methyl-2-[3-methyl-4-(4-methylpiperazin-1-yl)anilino]-6-(2-methylphenyl)pyrido[2,3-d]pyrimidin-7-one Chemical compound C(C)(=O)N1C[C@H](CCC1)N1C(C(=C(C2=C1N=C(N=C2)NC1=CC(=C(C=C1)N1CCN(CC1)C)C)C)C1=C(C=CC=C1)C)=O FYSKSIKODQJXSY-MHZLTWQESA-N 0.000 description 1
- WKPFYHFSVDWPGJ-VWLOTQADSA-N 8-[(3S)-1-acetylpiperidin-3-yl]-6-(2-fluoropyridin-4-yl)-5-methyl-2-[3-methyl-4-(4-methylpiperazin-1-yl)anilino]pyrido[2,3-d]pyrimidin-7-one Chemical compound C(C)(=O)N1C[C@H](CCC1)N1C(C(=C(C2=C1N=C(N=C2)NC1=CC(=C(C=C1)N1CCN(CC1)C)C)C)C1=CC(=NC=C1)F)=O WKPFYHFSVDWPGJ-VWLOTQADSA-N 0.000 description 1
- GWBPSPSEUPSEDT-MHZLTWQESA-N 8-[(3S)-1-acetylpiperidin-3-yl]-6-(3-chlorophenyl)-2-[3-methyl-4-(4-methylpiperazin-1-yl)anilino]pyrido[2,3-d]pyrimidin-7-one Chemical compound C(C)(=O)N1C[C@H](CCC1)N1C(C(=CC2=C1N=C(N=C2)NC1=CC(=C(C=C1)N1CCN(CC1)C)C)C1=CC(=CC=C1)Cl)=O GWBPSPSEUPSEDT-MHZLTWQESA-N 0.000 description 1
- FUHGBLURAFOORV-DEOSSOPVSA-N 8-[(3S)-1-acetylpyrrolidin-3-yl]-6-(2-chlorophenyl)-2-[3-methyl-4-(4-methylpiperazin-1-yl)anilino]pyrido[2,3-d]pyrimidin-7-one Chemical compound C(C)(=O)N1C[C@H](CC1)N1C(C(=CC2=C1N=C(N=C2)NC1=CC(=C(C=C1)N1CCN(CC1)C)C)C1=C(C=CC=C1)Cl)=O FUHGBLURAFOORV-DEOSSOPVSA-N 0.000 description 1
- MKBLHFILKIKSQM-UHFFFAOYSA-N 9-methyl-3-[(2-methyl-1h-imidazol-3-ium-3-yl)methyl]-2,3-dihydro-1h-carbazol-4-one;chloride Chemical compound Cl.CC1=NC=CN1CC1C(=O)C(C=2C(=CC=CC=2)N2C)=C2CC1 MKBLHFILKIKSQM-UHFFFAOYSA-N 0.000 description 1
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 1
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 1
- ULXXDDBFHOBEHA-ONEGZZNKSA-N Afatinib Chemical compound N1=CN=C2C=C(OC3COCC3)C(NC(=O)/C=C/CN(C)C)=CC2=C1NC1=CC=C(F)C(Cl)=C1 ULXXDDBFHOBEHA-ONEGZZNKSA-N 0.000 description 1
- OGSPWJRAVKPPFI-UHFFFAOYSA-N Alendronic Acid Chemical compound NCCCC(O)(P(O)(O)=O)P(O)(O)=O OGSPWJRAVKPPFI-UHFFFAOYSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Natural products OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 1
- 239000005528 B01AC05 - Ticlopidine Substances 0.000 description 1
- 229940118364 Bcr-Abl inhibitor Drugs 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- FOFMTJGIXYPMFM-UHFFFAOYSA-N C(C)(=O)N1CCC(CC1)N1C(C(=C(C2=C1N=C(N=C2)NC1=CC(=C(C=C1)N1CCN(CC1)C)C)C)C1=C(C=CC=C1)Cl)=O Chemical compound C(C)(=O)N1CCC(CC1)N1C(C(=C(C2=C1N=C(N=C2)NC1=CC(=C(C=C1)N1CCN(CC1)C)C)C)C1=C(C=CC=C1)Cl)=O FOFMTJGIXYPMFM-UHFFFAOYSA-N 0.000 description 1
- QTWMGCPPDNHAQY-VWLOTQADSA-N C(C)(=O)N1C[C@H](CCC1)N1C(C(=C(C2=C1N=C(N=C2)NC1=CC(=C(C=C1)N1CCN(CC1)C)C)C)C1=C(C=C(C=C1)Cl)Cl)=O Chemical compound C(C)(=O)N1C[C@H](CCC1)N1C(C(=C(C2=C1N=C(N=C2)NC1=CC(=C(C=C1)N1CCN(CC1)C)C)C)C1=C(C=C(C=C1)Cl)Cl)=O QTWMGCPPDNHAQY-VWLOTQADSA-N 0.000 description 1
- LSHKSCVKTQFCMW-VWLOTQADSA-N C(C)(=O)N1C[C@H](CCC1)N1C(C(=C(C2=C1N=C(N=C2)NC1=CC(=C(C=C1)N1CCN(CC1)C)C)C)C1=C(C=CC(=C1)Cl)Cl)=O Chemical compound C(C)(=O)N1C[C@H](CCC1)N1C(C(=C(C2=C1N=C(N=C2)NC1=CC(=C(C=C1)N1CCN(CC1)C)C)C)C1=C(C=CC(=C1)Cl)Cl)=O LSHKSCVKTQFCMW-VWLOTQADSA-N 0.000 description 1
- ONLVRHIJSCGHOC-VWLOTQADSA-N C(C)(=O)N1C[C@H](CCC1)N1C(C(=C(C2=C1N=C(N=C2)NC1=CC(=C(C=C1)N1CCN(CC1)C)C)C)C1=C(C=CC=C1)Cl)=O Chemical compound C(C)(=O)N1C[C@H](CCC1)N1C(C(=C(C2=C1N=C(N=C2)NC1=CC(=C(C=C1)N1CCN(CC1)C)C)C)C1=C(C=CC=C1)Cl)=O ONLVRHIJSCGHOC-VWLOTQADSA-N 0.000 description 1
- TVHAQGOCBGRJKW-VWLOTQADSA-N C(C)(=O)N1C[C@H](CCC1)N1C(C(=C(C2=C1N=C(N=C2)NC1=CC(=C(C=C1)N1CCN(CC1)C)C)C)C1=C(C=CC=C1)F)=O Chemical compound C(C)(=O)N1C[C@H](CCC1)N1C(C(=C(C2=C1N=C(N=C2)NC1=CC(=C(C=C1)N1CCN(CC1)C)C)C)C1=C(C=CC=C1)F)=O TVHAQGOCBGRJKW-VWLOTQADSA-N 0.000 description 1
- SPRFVSJWHHJFCY-DEOSSOPVSA-N C(C)(=O)N1C[C@H](CCC1)N1C(C(=C(C2=C1N=C(N=C2)NC1=CC(=C(C=C1)N1CCN(CC1)C)C)C)C1=C(C=NC=C1)Cl)=O Chemical compound C(C)(=O)N1C[C@H](CCC1)N1C(C(=C(C2=C1N=C(N=C2)NC1=CC(=C(C=C1)N1CCN(CC1)C)C)C)C1=C(C=NC=C1)Cl)=O SPRFVSJWHHJFCY-DEOSSOPVSA-N 0.000 description 1
- RLRHCDTTWILSID-MHZLTWQESA-N C(C)(=O)N1C[C@H](CCC1)N1C(C(=C(C2=C1N=C(N=C2)NC1=CC(=C(C=C1)N1CCN(CC1)C)C)C)C1=CC(=CC(=C1)Cl)Cl)=O Chemical compound C(C)(=O)N1C[C@H](CCC1)N1C(C(=C(C2=C1N=C(N=C2)NC1=CC(=C(C=C1)N1CCN(CC1)C)C)C)C1=CC(=CC(=C1)Cl)Cl)=O RLRHCDTTWILSID-MHZLTWQESA-N 0.000 description 1
- ADWYBDAJGGYXNS-MHZLTWQESA-N C(C)(=O)N1C[C@H](CCC1)N1C(C(=C(C2=C1N=C(N=C2)NC1=CC(=C(C=C1)N1CCN(CC1)C)C)C)C1=CC(=CC=C1)Cl)=O Chemical compound C(C)(=O)N1C[C@H](CCC1)N1C(C(=C(C2=C1N=C(N=C2)NC1=CC(=C(C=C1)N1CCN(CC1)C)C)C)C1=CC(=CC=C1)Cl)=O ADWYBDAJGGYXNS-MHZLTWQESA-N 0.000 description 1
- BNAOYAXSZIBYHJ-MHZLTWQESA-N C(C)(=O)N1C[C@H](CCC1)N1C(C(=C(C2=C1N=C(N=C2)NC1=CC(=C(C=C1)N1CCN(CC1)C)C)C)C1=CC=C(C=C1)Cl)=O Chemical compound C(C)(=O)N1C[C@H](CCC1)N1C(C(=C(C2=C1N=C(N=C2)NC1=CC(=C(C=C1)N1CCN(CC1)C)C)C)C1=CC=C(C=C1)Cl)=O BNAOYAXSZIBYHJ-MHZLTWQESA-N 0.000 description 1
- UNIXXCQQDPWJJP-MHZLTWQESA-N C(C)(=O)N1C[C@H](CCC1)N1C(C(=C(C2=C1N=C(N=C2)NC1=CC(=C(C=C1)N1CCN(CC1)C)C)C)C1=CC=CC=C1)=O Chemical compound C(C)(=O)N1C[C@H](CCC1)N1C(C(=C(C2=C1N=C(N=C2)NC1=CC(=C(C=C1)N1CCN(CC1)C)C)C)C1=CC=CC=C1)=O UNIXXCQQDPWJJP-MHZLTWQESA-N 0.000 description 1
- RGYHKQRKCPPSCM-SANMLTNESA-N C(C)(=O)N1C[C@H](CCC1)N1C(C(=C(C2=C1N=C(N=C2)NC1=CC(=C(C=C1)N1CCN(CC1)C)C)C)C1=CC=NC=C1)=O Chemical compound C(C)(=O)N1C[C@H](CCC1)N1C(C(=C(C2=C1N=C(N=C2)NC1=CC(=C(C=C1)N1CCN(CC1)C)C)C)C1=CC=NC=C1)=O RGYHKQRKCPPSCM-SANMLTNESA-N 0.000 description 1
- KKZMZWJNMYGFSR-VWLOTQADSA-N C(C)(=O)N1C[C@H](CCC1)N1C(C(=C(C2=C1N=C(N=C2)NC1=CC(=C(C=C1)N1CCN(CC1)C)C)C)C1=COC=C1)=O Chemical compound C(C)(=O)N1C[C@H](CCC1)N1C(C(=C(C2=C1N=C(N=C2)NC1=CC(=C(C=C1)N1CCN(CC1)C)C)C)C1=COC=C1)=O KKZMZWJNMYGFSR-VWLOTQADSA-N 0.000 description 1
- OMOHYGQGEQMCOC-VWLOTQADSA-N C(C)(=O)N1C[C@H](CCC1)N1C(C(=C(C2=C1N=C(N=C2)NC1=CC(=C(C=C1)N1CCN(CC1)C)C)C)C=1C=NC(=NC=1)OC)=O Chemical compound C(C)(=O)N1C[C@H](CCC1)N1C(C(=C(C2=C1N=C(N=C2)NC1=CC(=C(C=C1)N1CCN(CC1)C)C)C)C=1C=NC(=NC=1)OC)=O OMOHYGQGEQMCOC-VWLOTQADSA-N 0.000 description 1
- CWSOMBXGYXNNCA-VWLOTQADSA-N C(C)(=O)N1C[C@H](CCC1)N1C(C(=CC2=C1N=C(N=C2)NC1=CC(=C(C=C1)N1CCN(CC1)C)C)C1=C(C=CC=C1)Cl)=O Chemical compound C(C)(=O)N1C[C@H](CCC1)N1C(C(=CC2=C1N=C(N=C2)NC1=CC(=C(C=C1)N1CCN(CC1)C)C)C1=C(C=CC=C1)Cl)=O CWSOMBXGYXNNCA-VWLOTQADSA-N 0.000 description 1
- MFSMBLYYNQWADD-NSHDSACASA-N C(C)(C)(C)OC(=O)N1C[C@H](CC1)NC1=NC(=NC=C1C=O)SC Chemical compound C(C)(C)(C)OC(=O)N1C[C@H](CC1)NC1=NC(=NC=C1C=O)SC MFSMBLYYNQWADD-NSHDSACASA-N 0.000 description 1
- CLSXMYVWLVCCGJ-NSHDSACASA-N C(C)OC(=O)C=1C(=NC(=NC=1)SC)N[C@@H]1CN(CC1)C(=O)OC(C)(C)C Chemical compound C(C)OC(=O)C=1C(=NC(=NC=1)SC)N[C@@H]1CN(CC1)C(=O)OC(C)(C)C CLSXMYVWLVCCGJ-NSHDSACASA-N 0.000 description 1
- 229940124204 C-kit inhibitor Drugs 0.000 description 1
- MMRJNHBNBAWAKV-UHFFFAOYSA-N C1(CCCCC1)N1C(C(=C(C2=C1N=C(N=C2)NC1=CC(=C(C=C1)N1CCN(CC1)C)C)C)C1=C(C=CC=C1)C)=O Chemical compound C1(CCCCC1)N1C(C(=C(C2=C1N=C(N=C2)NC1=CC(=C(C=C1)N1CCN(CC1)C)C)C)C1=C(C=CC=C1)C)=O MMRJNHBNBAWAKV-UHFFFAOYSA-N 0.000 description 1
- XZDGEKHDTLROBA-UHFFFAOYSA-N C1(CCCCC1)N1C(C(=C(C2=C1N=C(N=C2)NC1=CC(=C(C=C1)N1CCN(CC1)C)C)C)C1=C(C=CC=C1)F)=O Chemical compound C1(CCCCC1)N1C(C(=C(C2=C1N=C(N=C2)NC1=CC(=C(C=C1)N1CCN(CC1)C)C)C)C1=C(C=CC=C1)F)=O XZDGEKHDTLROBA-UHFFFAOYSA-N 0.000 description 1
- CZLXOYYQGPJXTL-UHFFFAOYSA-N C1(CCCCC1)N1C(C(=C(C2=C1N=C(N=C2)NC1=CC(=C(C=C1)N1CCN(CC1)C)C)C)C1=C(C=CC=C1)OC)=O Chemical compound C1(CCCCC1)N1C(C(=C(C2=C1N=C(N=C2)NC1=CC(=C(C=C1)N1CCN(CC1)C)C)C)C1=C(C=CC=C1)OC)=O CZLXOYYQGPJXTL-UHFFFAOYSA-N 0.000 description 1
- WHZYQWDWXKZQMV-UHFFFAOYSA-N C1(CCCCC1)N1C(C=C(C2=C1N=C(N=C2)NC1=CC(=C(C=C1)N1CCN(CC1)C)C)C)=O Chemical compound C1(CCCCC1)N1C(C=C(C2=C1N=C(N=C2)NC1=CC(=C(C=C1)N1CCN(CC1)C)C)C)=O WHZYQWDWXKZQMV-UHFFFAOYSA-N 0.000 description 1
- ORTAXXZJVCPZJF-VIFPVBQESA-N CC(C)N1C[C@@H](C)CCC1 Chemical compound CC(C)N1C[C@@H](C)CCC1 ORTAXXZJVCPZJF-VIFPVBQESA-N 0.000 description 1
- UQUHQKVINDTPNE-UHFFFAOYSA-N CC(CC1)CCN1N Chemical compound CC(CC1)CCN1N UQUHQKVINDTPNE-UHFFFAOYSA-N 0.000 description 1
- KFMLCIWUTYZMQU-MHZLTWQESA-N CC1=C(C(N(C=2N=C(N=CC=21)NC1=CC(=C(C=C1)N1CCN(CC1)C)C)[C@@H]1CN(CCC1)C(CC)=O)=O)C1=C(C=CC=C1)C Chemical compound CC1=C(C(N(C=2N=C(N=CC=21)NC1=CC(=C(C=C1)N1CCN(CC1)C)C)[C@@H]1CN(CCC1)C(CC)=O)=O)C1=C(C=CC=C1)C KFMLCIWUTYZMQU-MHZLTWQESA-N 0.000 description 1
- FZFBDQZLVGZMJL-MHZLTWQESA-N CC1=C(C(N(C=2N=C(N=CC=21)NC1=CC(=C(C=C1)N1CCN(CC1)C)C)[C@@H]1CN(CCC1)C(CC)=O)=O)C1=CC=CC=C1 Chemical compound CC1=C(C(N(C=2N=C(N=CC=21)NC1=CC(=C(C=C1)N1CCN(CC1)C)C)[C@@H]1CN(CCC1)C(CC)=O)=O)C1=CC=CC=C1 FZFBDQZLVGZMJL-MHZLTWQESA-N 0.000 description 1
- NUSVODNLWNYCTF-VWLOTQADSA-N CCC(N(CCC1)C[C@H]1N(c(nc(Nc1ncc(CN2CCN(CC)CC2)cc1)nc1)c1C(C)=C1c2ccccc2Cl)C1=O)=O Chemical compound CCC(N(CCC1)C[C@H]1N(c(nc(Nc1ncc(CN2CCN(CC)CC2)cc1)nc1)c1C(C)=C1c2ccccc2Cl)C1=O)=O NUSVODNLWNYCTF-VWLOTQADSA-N 0.000 description 1
- SKLMITJXEKMTJJ-VWLOTQADSA-N COC1=NC=C(C=N1)C1=C(C2=C(N=C(N=C2)NC2=CC(=C(C=C2)N2CCN(CC2)C)C)N(C1=O)[C@@H]1CN(CCC1)C(CC)=O)C Chemical compound COC1=NC=C(C=N1)C1=C(C2=C(N=C(N=C2)NC2=CC(=C(C=C2)N2CCN(CC2)C)C)N(C1=O)[C@@H]1CN(CCC1)C(CC)=O)C SKLMITJXEKMTJJ-VWLOTQADSA-N 0.000 description 1
- FVLVBPDQNARYJU-XAHDHGMMSA-N C[C@H]1CCC(CC1)NC(=O)N(CCCl)N=O Chemical compound C[C@H]1CCC(CC1)NC(=O)N(CCCl)N=O FVLVBPDQNARYJU-XAHDHGMMSA-N 0.000 description 1
- 102000055006 Calcitonin Human genes 0.000 description 1
- 108060001064 Calcitonin Proteins 0.000 description 1
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 description 1
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241001250090 Capra ibex Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 1
- WTFBWGSAQFIDDP-HCGLCNNCSA-N Cc(cc(cc1)Nc(nc2)nc(N3[C@H](CC4)CC[C@@H]4N)c2C(C)=C(c2ccccc2Cl)C3=O)c1N1CCN(C)CC1 Chemical compound Cc(cc(cc1)Nc(nc2)nc(N3[C@H](CC4)CC[C@@H]4N)c2C(C)=C(c2ccccc2Cl)C3=O)c1N1CCN(C)CC1 WTFBWGSAQFIDDP-HCGLCNNCSA-N 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- QVHBCTPFTUVSOE-VWLOTQADSA-N ClC1=C(C=C(C=C1)Cl)C1=C(C2=C(N=C(N=C2)NC2=CC(=C(C=C2)N2CCN(CC2)C)C)N(C1=O)[C@@H]1CN(CCC1)C(CC)=O)C Chemical compound ClC1=C(C=C(C=C1)Cl)C1=C(C2=C(N=C(N=C2)NC2=CC(=C(C=C2)N2CCN(CC2)C)C)N(C1=O)[C@@H]1CN(CCC1)C(CC)=O)C QVHBCTPFTUVSOE-VWLOTQADSA-N 0.000 description 1
- HATUDAXQDCFKSG-VWLOTQADSA-N ClC1=C(C=CC(=C1)Cl)C1=C(C2=C(N=C(N=C2)NC2=CC(=C(C=C2)N2CCN(CC2)C)C)N(C1=O)[C@@H]1CN(CCC1)C(CC)=O)C Chemical compound ClC1=C(C=CC(=C1)Cl)C1=C(C2=C(N=C(N=C2)NC2=CC(=C(C=C2)N2CCN(CC2)C)C)N(C1=O)[C@@H]1CN(CCC1)C(CC)=O)C HATUDAXQDCFKSG-VWLOTQADSA-N 0.000 description 1
- GOSYLIGICHPFQB-VWLOTQADSA-N ClC1=C(C=CC(=C1)OC)C1=C(C2=C(N=C(N=C2)NC2=CC(=C(C=C2)N2CCN(CC2)C)C)N(C1=O)[C@@H]1CN(CCC1)C(CC)=O)C Chemical compound ClC1=C(C=CC(=C1)OC)C1=C(C2=C(N=C(N=C2)NC2=CC(=C(C=C2)N2CCN(CC2)C)C)N(C1=O)[C@@H]1CN(CCC1)C(CC)=O)C GOSYLIGICHPFQB-VWLOTQADSA-N 0.000 description 1
- MBGCWXDPCICALX-VWLOTQADSA-N ClC1=C(C=CC=C1)C1=C(C2=C(N=C(N=C2)NC2=C(C=C(C=C2)N2CCN(CC2)C)C)N(C1=O)[C@@H]1CN(CCC1)C(CC)=O)C Chemical compound ClC1=C(C=CC=C1)C1=C(C2=C(N=C(N=C2)NC2=C(C=C(C=C2)N2CCN(CC2)C)C)N(C1=O)[C@@H]1CN(CCC1)C(CC)=O)C MBGCWXDPCICALX-VWLOTQADSA-N 0.000 description 1
- LQOPJJBCHZLSIN-NDEPHWFRSA-N ClC1=C(C=CC=C1)C1=C(C2=C(N=C(N=C2)NC2=CC(=C(C=C2)CN2CCN(CC2)CC)C)N(C1=O)[C@@H]1CN(CCC1)C(CC)=O)C Chemical compound ClC1=C(C=CC=C1)C1=C(C2=C(N=C(N=C2)NC2=CC(=C(C=C2)CN2CCN(CC2)CC)C)N(C1=O)[C@@H]1CN(CCC1)C(CC)=O)C LQOPJJBCHZLSIN-NDEPHWFRSA-N 0.000 description 1
- BKUXKNQLCDTROT-VWLOTQADSA-N ClC1=C(C=CC=C1)C1=C(C2=C(N=C(N=C2)NC2=CC(=C(C=C2)N(C)CCN(C)C)C)N(C1=O)[C@@H]1CN(CCC1)C(CC)=O)C Chemical compound ClC1=C(C=CC=C1)C1=C(C2=C(N=C(N=C2)NC2=CC(=C(C=C2)N(C)CCN(C)C)C)N(C1=O)[C@@H]1CN(CCC1)C(CC)=O)C BKUXKNQLCDTROT-VWLOTQADSA-N 0.000 description 1
- MNRQIEXGUHFIQJ-MHZLTWQESA-N ClC1=C(C=CC=C1)C1=C(C2=C(N=C(N=C2)NC2=CC(=C(C=C2)N2CC3(C2)CCN(CC3)C)C)N(C1=O)[C@@H]1CN(CCC1)C(CC)=O)C Chemical compound ClC1=C(C=CC=C1)C1=C(C2=C(N=C(N=C2)NC2=CC(=C(C=C2)N2CC3(C2)CCN(CC3)C)C)N(C1=O)[C@@H]1CN(CCC1)C(CC)=O)C MNRQIEXGUHFIQJ-MHZLTWQESA-N 0.000 description 1
- POVAXOXGYVGREN-MHZLTWQESA-N ClC1=C(C=CC=C1)C1=C(C2=C(N=C(N=C2)NC2=CC(=C(C=C2)N2CCC(CC2)N(C)C)C)N(C1=O)[C@@H]1CN(CCC1)C(CC)=O)C Chemical compound ClC1=C(C=CC=C1)C1=C(C2=C(N=C(N=C2)NC2=CC(=C(C=C2)N2CCC(CC2)N(C)C)C)N(C1=O)[C@@H]1CN(CCC1)C(CC)=O)C POVAXOXGYVGREN-MHZLTWQESA-N 0.000 description 1
- MURLKTGLBOQISA-LJAQVGFWSA-N ClC1=C(C=CC=C1)C1=C(C2=C(N=C(N=C2)NC2=CC(=C(C=C2)N2CCC3(CC2)CCN(CC3)C)C)N(C1=O)[C@@H]1CN(CCC1)C(CC)=O)C Chemical compound ClC1=C(C=CC=C1)C1=C(C2=C(N=C(N=C2)NC2=CC(=C(C=C2)N2CCC3(CC2)CCN(CC3)C)C)N(C1=O)[C@@H]1CN(CCC1)C(CC)=O)C MURLKTGLBOQISA-LJAQVGFWSA-N 0.000 description 1
- UWJHVZNNTOZJIK-QHCPKHFHSA-N ClC1=C(C=CC=C1)C1=C(C2=C(N=C(N=C2)NC2=CC(=C(C=C2)N2CCN(CC2)C)C(F)(F)F)N(C1=O)[C@@H]1CN(CCC1)C(CC)=O)C Chemical compound ClC1=C(C=CC=C1)C1=C(C2=C(N=C(N=C2)NC2=CC(=C(C=C2)N2CCN(CC2)C)C(F)(F)F)N(C1=O)[C@@H]1CN(CCC1)C(CC)=O)C UWJHVZNNTOZJIK-QHCPKHFHSA-N 0.000 description 1
- JYXRNVDDQWSADT-UHFFFAOYSA-N ClC1=C(C=CC=C1)C1=C(C2=C(N=C(N=C2)NC2=CC(=C(C=C2)N2CCN(CC2)C)C)N(C1=O)C1CCCC1)C Chemical compound ClC1=C(C=CC=C1)C1=C(C2=C(N=C(N=C2)NC2=CC(=C(C=C2)N2CCN(CC2)C)C)N(C1=O)C1CCCC1)C JYXRNVDDQWSADT-UHFFFAOYSA-N 0.000 description 1
- NFXBHPGRNDFIQL-UHFFFAOYSA-N ClC1=C(C=CC=C1)C1=C(C2=C(N=C(N=C2)NC2=CC(=C(C=C2)N2CCN(CC2)C)C)N(C1=O)C1CCCCC1)C Chemical compound ClC1=C(C=CC=C1)C1=C(C2=C(N=C(N=C2)NC2=CC(=C(C=C2)N2CCN(CC2)C)C)N(C1=O)C1CCCCC1)C NFXBHPGRNDFIQL-UHFFFAOYSA-N 0.000 description 1
- SHRMORKMVBKJGP-QHCPKHFHSA-N ClC1=C(C=CC=C1)C1=C(C2=C(N=C(N=C2)NC2=CC(=C(C=C2)N2CCN(CC2)C)F)N(C1=O)[C@@H]1CN(CCC1)C(CC)=O)C Chemical compound ClC1=C(C=CC=C1)C1=C(C2=C(N=C(N=C2)NC2=CC(=C(C=C2)N2CCN(CC2)C)F)N(C1=O)[C@@H]1CN(CCC1)C(CC)=O)C SHRMORKMVBKJGP-QHCPKHFHSA-N 0.000 description 1
- KIFWDDDVDIOPJM-DEOSSOPVSA-N ClC1=C(C=CC=C1)C1=C(C2=C(N=C(N=C2)NC2=CC(=C(C=C2)N2CCN(CC2)C)OC)N(C1=O)[C@@H]1CN(CCC1)C(CC)=O)C Chemical compound ClC1=C(C=CC=C1)C1=C(C2=C(N=C(N=C2)NC2=CC(=C(C=C2)N2CCN(CC2)C)OC)N(C1=O)[C@@H]1CN(CCC1)C(CC)=O)C KIFWDDDVDIOPJM-DEOSSOPVSA-N 0.000 description 1
- ILUQXLWOFZVYNF-OZXSUGGESA-N ClC1=C(C=CC=C1)C1=C(C2=C(N=C(N=C2)NC2=CC(=C(C=C2)N2C[C@@H](N(CC2)C)C)C)N(C1=O)[C@@H]1CN(CCC1)C(CC)=O)C Chemical compound ClC1=C(C=CC=C1)C1=C(C2=C(N=C(N=C2)NC2=CC(=C(C=C2)N2C[C@@H](N(CC2)C)C)C)N(C1=O)[C@@H]1CN(CCC1)C(CC)=O)C ILUQXLWOFZVYNF-OZXSUGGESA-N 0.000 description 1
- YIWHDLUIROSIBY-XFAFFCHDSA-N ClC1=C(C=CC=C1)C1=C(C2=C(N=C(N=C2)NC2=CC(=C(C=C2)N2C[C@@H](N([C@@H](C2)C)C)C)C)N(C1=O)[C@@H]1CN(CCC1)C(CC)=O)C Chemical compound ClC1=C(C=CC=C1)C1=C(C2=C(N=C(N=C2)NC2=CC(=C(C=C2)N2C[C@@H](N([C@@H](C2)C)C)C)C)N(C1=O)[C@@H]1CN(CCC1)C(CC)=O)C YIWHDLUIROSIBY-XFAFFCHDSA-N 0.000 description 1
- YYUSPHBQWJNGAH-WEWMWRJBSA-N ClC1=C(C=CC=C1)C1=C(C2=C(N=C(N=C2)NC2=CC(=C(C=C2)N2C[C@@H]3CN(C[C@@H]3C2)C)C)N(C1=O)[C@@H]1CN(CCC1)C(CC)=O)C Chemical compound ClC1=C(C=CC=C1)C1=C(C2=C(N=C(N=C2)NC2=CC(=C(C=C2)N2C[C@@H]3CN(C[C@@H]3C2)C)C)N(C1=O)[C@@H]1CN(CCC1)C(CC)=O)C YYUSPHBQWJNGAH-WEWMWRJBSA-N 0.000 description 1
- ILUQXLWOFZVYNF-BVAGGSTKSA-N ClC1=C(C=CC=C1)C1=C(C2=C(N=C(N=C2)NC2=CC(=C(C=C2)N2C[C@H](N(CC2)C)C)C)N(C1=O)[C@@H]1CN(CCC1)C(CC)=O)C Chemical compound ClC1=C(C=CC=C1)C1=C(C2=C(N=C(N=C2)NC2=CC(=C(C=C2)N2C[C@H](N(CC2)C)C)C)N(C1=O)[C@@H]1CN(CCC1)C(CC)=O)C ILUQXLWOFZVYNF-BVAGGSTKSA-N 0.000 description 1
- VCMLGQDATSVUME-QHCPKHFHSA-N ClC1=C(C=CC=C1)C1=C(C2=C(N=C(N=C2)NC2=NC(=C(C=C2)N2CCN(CC2)C)C)N(C1=O)[C@@H]1CN(CCC1)C(CC)=O)C Chemical compound ClC1=C(C=CC=C1)C1=C(C2=C(N=C(N=C2)NC2=NC(=C(C=C2)N2CCN(CC2)C)C)N(C1=O)[C@@H]1CN(CCC1)C(CC)=O)C VCMLGQDATSVUME-QHCPKHFHSA-N 0.000 description 1
- RGLMWFDEHYRHKP-QFIPXVFZSA-N ClC1=C(C=CC=C1)C1=C(C2=C(N=C(N=C2)NC2=NC=C(C=C2)N2CCNCC2)N(C1=O)[C@@H]1CN(CCC1)C(CC)=O)C Chemical compound ClC1=C(C=CC=C1)C1=C(C2=C(N=C(N=C2)NC2=NC=C(C=C2)N2CCNCC2)N(C1=O)[C@@H]1CN(CCC1)C(CC)=O)C RGLMWFDEHYRHKP-QFIPXVFZSA-N 0.000 description 1
- SOUCANARWNKEIL-NRFANRHFSA-N ClC1=C(C=CC=C1)C1=C(C2=C(N=C(N=C2)NC=2C=NN(C=2)CCN(C)C)N(C1=O)[C@@H]1CN(CCC1)C(CC)=O)C Chemical compound ClC1=C(C=CC=C1)C1=C(C2=C(N=C(N=C2)NC=2C=NN(C=2)CCN(C)C)N(C1=O)[C@@H]1CN(CCC1)C(CC)=O)C SOUCANARWNKEIL-NRFANRHFSA-N 0.000 description 1
- FJIWMQVLOSNNHU-QHCPKHFHSA-N ClC1=C(C=CC=C1)C1=C(C2=C(N=C(N=C2)NC=2C=NN(C=2)CCN(CC)CC)N(C1=O)[C@@H]1CN(CCC1)C(CC)=O)C Chemical compound ClC1=C(C=CC=C1)C1=C(C2=C(N=C(N=C2)NC=2C=NN(C=2)CCN(CC)CC)N(C1=O)[C@@H]1CN(CCC1)C(CC)=O)C FJIWMQVLOSNNHU-QHCPKHFHSA-N 0.000 description 1
- WRHNDRRNLPCUER-DEOSSOPVSA-N ClC1=C(C=CC=C1)C1=CC2=C(N=C(N=C2)NC2=CC(=C(C=C2)N2CCN(CC2)C)C)N(C1=O)[C@@H]1CN(CC1)C(CC)=O Chemical compound ClC1=C(C=CC=C1)C1=CC2=C(N=C(N=C2)NC2=CC(=C(C=C2)N2CCN(CC2)C)C)N(C1=O)[C@@H]1CN(CC1)C(CC)=O WRHNDRRNLPCUER-DEOSSOPVSA-N 0.000 description 1
- IZRVBXHMMRPQHU-VWLOTQADSA-N ClC1=C(C=CC=C1)C1=CC2=C(N=C(N=C2)NC2=CC(=C(C=C2)N2CCN(CC2)C)C)N(C1=O)[C@@H]1CN(CCC1)C(CC)=O Chemical compound ClC1=C(C=CC=C1)C1=CC2=C(N=C(N=C2)NC2=CC(=C(C=C2)N2CCN(CC2)C)C)N(C1=O)[C@@H]1CN(CCC1)C(CC)=O IZRVBXHMMRPQHU-VWLOTQADSA-N 0.000 description 1
- REZLHNFSSBBSFC-DEOSSOPVSA-N ClC1=C(C=CC=C1F)C1=C(C2=C(N=C(N=C2)NC2=CC(=C(C=C2)N2CCN(CC2)C)C)N(C1=O)[C@@H]1CN(CCC1)C(CC)=O)C Chemical compound ClC1=C(C=CC=C1F)C1=C(C2=C(N=C(N=C2)NC2=CC(=C(C=C2)N2CCN(CC2)C)C)N(C1=O)[C@@H]1CN(CCC1)C(CC)=O)C REZLHNFSSBBSFC-DEOSSOPVSA-N 0.000 description 1
- UCYKGTYLAPUFEV-SDHOMARFSA-N ClC1=C(C=CC=C1F)C1=C(C2=C(N=C(N=C2)NC2=CC(=C(C=C2)N2[C@@H]3CN([C@H](C2)C3)C)C)N(C1=O)[C@@H]1CN(CCC1)C(CC)=O)C Chemical compound ClC1=C(C=CC=C1F)C1=C(C2=C(N=C(N=C2)NC2=CC(=C(C=C2)N2[C@@H]3CN([C@H](C2)C3)C)C)N(C1=O)[C@@H]1CN(CCC1)C(CC)=O)C UCYKGTYLAPUFEV-SDHOMARFSA-N 0.000 description 1
- JJLUXABUOYIZQS-UHFFFAOYSA-N ClC1=CC=C(C=C1)C1=C(C2=C(N=C(N=C2)NC2=CC(=C(C=C2)N2CCN(CC2)C)C)N(C1=O)C1CCCCC1)C Chemical compound ClC1=CC=C(C=C1)C1=C(C2=C(N=C(N=C2)NC2=CC(=C(C=C2)N2CCN(CC2)C)C)N(C1=O)C1CCCCC1)C JJLUXABUOYIZQS-UHFFFAOYSA-N 0.000 description 1
- VSSYQQWOYOREIW-MHZLTWQESA-N ClC1=CC=C(C=C1)C1=C(C2=C(N=C(N=C2)NC2=CC(=C(C=C2)N2CCN(CC2)C)C)N(C1=O)[C@@H]1CN(CCC1)C(CC)=O)C Chemical compound ClC1=CC=C(C=C1)C1=C(C2=C(N=C(N=C2)NC2=CC(=C(C=C2)N2CCN(CC2)C)C)N(C1=O)[C@@H]1CN(CCC1)C(CC)=O)C VSSYQQWOYOREIW-MHZLTWQESA-N 0.000 description 1
- IZPIWSCZMWLGJD-MHZLTWQESA-N ClC=1C=C(C=C(C=1)Cl)C1=C(C2=C(N=C(N=C2)NC2=CC(=C(C=C2)N2CCN(CC2)C)C)N(C1=O)[C@@H]1CN(CCC1)C(CC)=O)C Chemical compound ClC=1C=C(C=C(C=1)Cl)C1=C(C2=C(N=C(N=C2)NC2=CC(=C(C=C2)N2CCN(CC2)C)C)N(C1=O)[C@@H]1CN(CCC1)C(CC)=O)C IZPIWSCZMWLGJD-MHZLTWQESA-N 0.000 description 1
- AVLRFKMFWITEIC-UHFFFAOYSA-N ClC=1C=C(C=CC=1)C1=C(C2=C(N=C(N=C2)NC2=CC(=C(C=C2)N2CCN(CC2)C)C)N(C1=O)C1CCCC1)C Chemical compound ClC=1C=C(C=CC=1)C1=C(C2=C(N=C(N=C2)NC2=CC(=C(C=C2)N2CCN(CC2)C)C)N(C1=O)C1CCCC1)C AVLRFKMFWITEIC-UHFFFAOYSA-N 0.000 description 1
- RZCYFNHJNHYEDN-MHZLTWQESA-N ClC=1C=C(C=CC=1)C1=CC2=C(N=C(N=C2)NC2=CC(=C(C=C2)N2CCN(CC2)C)C)N(C1=O)[C@@H]1CN(CCC1)C(CC)=O Chemical compound ClC=1C=C(C=CC=1)C1=CC2=C(N=C(N=C2)NC2=CC(=C(C=C2)N2CCN(CC2)C)C)N(C1=O)[C@@H]1CN(CCC1)C(CC)=O RZCYFNHJNHYEDN-MHZLTWQESA-N 0.000 description 1
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 1
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 101710112752 Cytotoxin Proteins 0.000 description 1
- 108010092160 Dactinomycin Proteins 0.000 description 1
- 108010019673 Darbepoetin alfa Proteins 0.000 description 1
- ZBNZXTGUTAYRHI-UHFFFAOYSA-N Dasatinib Chemical compound C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1Cl ZBNZXTGUTAYRHI-UHFFFAOYSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 102000012199 E3 ubiquitin-protein ligase Mdm2 Human genes 0.000 description 1
- 108050002772 E3 ubiquitin-protein ligase Mdm2 Proteins 0.000 description 1
- 102000003951 Erythropoietin Human genes 0.000 description 1
- 108090000394 Erythropoietin Proteins 0.000 description 1
- BFPYWIDHMRZLRN-SLHNCBLASA-N Ethinyl estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 BFPYWIDHMRZLRN-SLHNCBLASA-N 0.000 description 1
- QXURLCUEMSJHGM-VWLOTQADSA-N FC1=C(C=CC=C1)C1=C(C2=C(N=C(N=C2)NC2=CC(=C(C=C2)N2CCN(CC2)C)C)N(C1=O)[C@@H]1CN(CCC1)C(CC)=O)C Chemical compound FC1=C(C=CC=C1)C1=C(C2=C(N=C(N=C2)NC2=CC(=C(C=C2)N2CCN(CC2)C)C)N(C1=O)[C@@H]1CN(CCC1)C(CC)=O)C QXURLCUEMSJHGM-VWLOTQADSA-N 0.000 description 1
- VWAIASRCXJNGBJ-VWLOTQADSA-N FC1=NC=CC(=C1)C1=C(C2=C(N=C(N=C2)NC2=CC(=C(C=C2)N2CCN(CC2)C)C)N(C1=O)[C@@H]1CN(CCC1)C(CC)=O)C Chemical compound FC1=NC=CC(=C1)C1=C(C2=C(N=C(N=C2)NC2=CC(=C(C=C2)N2CCN(CC2)C)C)N(C1=O)[C@@H]1CN(CCC1)C(CC)=O)C VWAIASRCXJNGBJ-VWLOTQADSA-N 0.000 description 1
- CWYNVVGOOAEACU-UHFFFAOYSA-N Fe2+ Chemical class [Fe+2] CWYNVVGOOAEACU-UHFFFAOYSA-N 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- VWUXBMIQPBEWFH-WCCTWKNTSA-N Fulvestrant Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)CC2=C1 VWUXBMIQPBEWFH-WCCTWKNTSA-N 0.000 description 1
- 206010051066 Gastrointestinal stromal tumour Diseases 0.000 description 1
- 229920002581 Glucomannan Polymers 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 108010069236 Goserelin Proteins 0.000 description 1
- BLCLNMBMMGCOAS-URPVMXJPSA-N Goserelin Chemical compound C([C@@H](C(=O)N[C@H](COC(C)(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NNC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 BLCLNMBMMGCOAS-URPVMXJPSA-N 0.000 description 1
- 235000001018 Hibiscus sabdariffa Nutrition 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000987586 Homo sapiens Eosinophil peroxidase Proteins 0.000 description 1
- 101000920686 Homo sapiens Erythropoietin Proteins 0.000 description 1
- 101001033249 Homo sapiens Interleukin-1 beta Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 108091069885 IAP family Proteins 0.000 description 1
- 102000040104 IAP family Human genes 0.000 description 1
- MPBVHIBUJCELCL-UHFFFAOYSA-N Ibandronate Chemical compound CCCCCN(C)CCC(O)(P(O)(O)=O)P(O)(O)=O MPBVHIBUJCELCL-UHFFFAOYSA-N 0.000 description 1
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 description 1
- XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 description 1
- 108010078049 Interferon alpha-2 Proteins 0.000 description 1
- 102100039350 Interferon alpha-7 Human genes 0.000 description 1
- 108090000467 Interferon-beta Proteins 0.000 description 1
- 102000003996 Interferon-beta Human genes 0.000 description 1
- 102000013462 Interleukin-12 Human genes 0.000 description 1
- 108010065805 Interleukin-12 Proteins 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- SHGAZHPCJJPHSC-NUEINMDLSA-N Isotretinoin Chemical compound OC(=O)C=C(C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-NUEINMDLSA-N 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 239000005511 L01XE05 - Sorafenib Substances 0.000 description 1
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 description 1
- 240000000599 Lentinula edodes Species 0.000 description 1
- HLFSDGLLUJUHTE-SNVBAGLBSA-N Levamisole Chemical compound C1([C@H]2CN3CCSC3=N2)=CC=CC=C1 HLFSDGLLUJUHTE-SNVBAGLBSA-N 0.000 description 1
- 241000408529 Libra Species 0.000 description 1
- GQYIWUVLTXOXAJ-UHFFFAOYSA-N Lomustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 229940124647 MEK inhibitor Drugs 0.000 description 1
- 229940124761 MMP inhibitor Drugs 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229920000877 Melamine resin Polymers 0.000 description 1
- XOGTZOOQQBDUSI-UHFFFAOYSA-M Mesna Chemical compound [Na+].[O-]S(=O)(=O)CCS XOGTZOOQQBDUSI-UHFFFAOYSA-M 0.000 description 1
- GCKMFJBGXUYNAG-HLXURNFRSA-N Methyltestosterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@](C)(O)[C@@]1(C)CC2 GCKMFJBGXUYNAG-HLXURNFRSA-N 0.000 description 1
- AYCPARAPKDAOEN-LJQANCHMSA-N N-[(1S)-2-(dimethylamino)-1-phenylethyl]-6,6-dimethyl-3-[(2-methyl-4-thieno[3,2-d]pyrimidinyl)amino]-1,4-dihydropyrrolo[3,4-c]pyrazole-5-carboxamide Chemical compound C1([C@H](NC(=O)N2C(C=3NN=C(NC=4C=5SC=CC=5N=C(C)N=4)C=3C2)(C)C)CN(C)C)=CC=CC=C1 AYCPARAPKDAOEN-LJQANCHMSA-N 0.000 description 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
- UEEJHVSXFDXPFK-UHFFFAOYSA-N N-dimethylaminoethanol Chemical compound CN(C)CCO UEEJHVSXFDXPFK-UHFFFAOYSA-N 0.000 description 1
- HTLZVHNRZJPSMI-UHFFFAOYSA-N N-ethylpiperidine Chemical compound CCN1CCCCC1 HTLZVHNRZJPSMI-UHFFFAOYSA-N 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- 108010021717 Nafarelin Proteins 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- YQOSEIGBOOGUDE-VWLOTQADSA-N O1C=C(C=C1)C1=C(C2=C(N=C(N=C2)NC2=CC(=C(C=C2)N2CCN(CC2)C)C)N(C1=O)[C@@H]1CN(CCC1)C(CC)=O)C Chemical compound O1C=C(C=C1)C1=C(C2=C(N=C(N=C2)NC2=CC(=C(C=C2)N2CCN(CC2)C)C)N(C1=O)[C@@H]1CN(CCC1)C(CC)=O)C YQOSEIGBOOGUDE-VWLOTQADSA-N 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- WYNCHZVNFNFDNH-UHFFFAOYSA-N Oxazolidine Chemical compound C1COCN1 WYNCHZVNFNFDNH-UHFFFAOYSA-N 0.000 description 1
- 239000012828 PI3K inhibitor Substances 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241000282373 Panthera pardus Species 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- KMSKQZKKOZQFFG-HSUXVGOQSA-N Pirarubicin Chemical compound O([C@H]1[C@@H](N)C[C@@H](O[C@H]1C)O[C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1CCCCO1 KMSKQZKKOZQFFG-HSUXVGOQSA-N 0.000 description 1
- 108010020346 Polyglutamic Acid Proteins 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 229940079156 Proteasome inhibitor Drugs 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 108010090931 Proto-Oncogene Proteins c-bcl-2 Proteins 0.000 description 1
- 102000013535 Proto-Oncogene Proteins c-bcl-2 Human genes 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 235000005291 Rumex acetosa Nutrition 0.000 description 1
- 240000007001 Rumex acetosella Species 0.000 description 1
- QCHFTSOMWOSFHM-UHFFFAOYSA-N SJ000285536 Natural products C1OC(=O)C(CC)C1CC1=CN=CN1C QCHFTSOMWOSFHM-UHFFFAOYSA-N 0.000 description 1
- 201000001880 Sexual dysfunction Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 206010041067 Small cell lung cancer Diseases 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 229940100514 Syk tyrosine kinase inhibitor Drugs 0.000 description 1
- 108700011582 TER 286 Proteins 0.000 description 1
- NAVMQTYZDKMPEU-UHFFFAOYSA-N Targretin Chemical compound CC1=CC(C(CCC2(C)C)(C)C)=C2C=C1C(=C)C1=CC=C(C(O)=O)C=C1 NAVMQTYZDKMPEU-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 description 1
- CBPNZQVSJQDFBE-FUXHJELOSA-N Temsirolimus Chemical compound C1C[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 CBPNZQVSJQDFBE-FUXHJELOSA-N 0.000 description 1
- PDMMFKSKQVNJMI-BLQWBTBKSA-N Testosterone propionate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](OC(=O)CC)[C@@]1(C)CC2 PDMMFKSKQVNJMI-BLQWBTBKSA-N 0.000 description 1
- FOCVUCIESVLUNU-UHFFFAOYSA-N Thiotepa Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 description 1
- 102000011923 Thyrotropin Human genes 0.000 description 1
- 108010061174 Thyrotropin Proteins 0.000 description 1
- DKJJVAGXPKPDRL-UHFFFAOYSA-N Tiludronic acid Chemical compound OP(O)(=O)C(P(O)(O)=O)SC1=CC=C(Cl)C=C1 DKJJVAGXPKPDRL-UHFFFAOYSA-N 0.000 description 1
- IVTVGDXNLFLDRM-HNNXBMFYSA-N Tomudex Chemical compound C=1C=C2NC(C)=NC(=O)C2=CC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)S1 IVTVGDXNLFLDRM-HNNXBMFYSA-N 0.000 description 1
- 102000000887 Transcription factor STAT Human genes 0.000 description 1
- 108050007918 Transcription factor STAT Proteins 0.000 description 1
- 108010050144 Triptorelin Pamoate Proteins 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 229940124674 VEGF-R inhibitor Drugs 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- LXRZVMYMQHNYJB-UNXOBOICSA-N [(1R,2S,4R)-4-[[5-[4-[(1R)-7-chloro-1,2,3,4-tetrahydroisoquinolin-1-yl]-5-methylthiophene-2-carbonyl]pyrimidin-4-yl]amino]-2-hydroxycyclopentyl]methyl sulfamate Chemical compound CC1=C(C=C(S1)C(=O)C1=C(N[C@H]2C[C@H](O)[C@@H](COS(N)(=O)=O)C2)N=CN=C1)[C@@H]1NCCC2=C1C=C(Cl)C=C2 LXRZVMYMQHNYJB-UNXOBOICSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- HPPONSCISKROOD-OYLNGHKZSA-N acetic acid;(2s)-n-[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2r)-1-[[(2s)-1-[[(2s)-1-[(2s)-2-[(2-amino-2-oxoethyl)carbamoyl]pyrrolidin-1-yl]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1h-indol-3-yl)-1-oxopropan-2-y Chemical compound CC(O)=O.C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 HPPONSCISKROOD-OYLNGHKZSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- DUYNJNWVGIWJRI-LJAQVGFWSA-N acolbifene Chemical compound C1=CC([C@H]2C(=C(C3=CC=C(O)C=C3O2)C)C=2C=CC(O)=CC=2)=CC=C1OCCN1CCCCC1 DUYNJNWVGIWJRI-LJAQVGFWSA-N 0.000 description 1
- 229950002421 acolbifene Drugs 0.000 description 1
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 238000004115 adherent culture Methods 0.000 description 1
- 229940062527 alendronate Drugs 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 description 1
- 229960003459 allopurinol Drugs 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- HAMNKKUPIHEESI-UHFFFAOYSA-N aminoguanidine Chemical compound NNC(N)=N HAMNKKUPIHEESI-UHFFFAOYSA-N 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 229960000510 ammonia Drugs 0.000 description 1
- 229960002550 amrubicin Drugs 0.000 description 1
- VJZITPJGSQKZMX-XDPRQOKASA-N amrubicin Chemical compound O([C@H]1C[C@](CC2=C(O)C=3C(=O)C4=CC=CC=C4C(=O)C=3C(O)=C21)(N)C(=O)C)[C@H]1C[C@H](O)[C@H](O)CO1 VJZITPJGSQKZMX-XDPRQOKASA-N 0.000 description 1
- XCPGHVQEEXUHNC-UHFFFAOYSA-N amsacrine Chemical compound COC1=CC(NS(C)(=O)=O)=CC=C1NC1=C(C=CC=C2)C2=NC2=CC=CC=C12 XCPGHVQEEXUHNC-UHFFFAOYSA-N 0.000 description 1
- 229960001220 amsacrine Drugs 0.000 description 1
- 229960002932 anastrozole Drugs 0.000 description 1
- YBBLVLTVTVSKRW-UHFFFAOYSA-N anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 description 1
- 239000004037 angiogenesis inhibitor Substances 0.000 description 1
- 229940121369 angiogenesis inhibitor Drugs 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- ATALOFNDEOCMKK-OITMNORJSA-N aprepitant Chemical compound O([C@@H]([C@@H]1C=2C=CC(F)=CC=2)O[C@H](C)C=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)CCN1CC1=NNC(=O)N1 ATALOFNDEOCMKK-OITMNORJSA-N 0.000 description 1
- 229960001372 aprepitant Drugs 0.000 description 1
- 229940115115 aranesp Drugs 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- UVJYAKBJSGRTHA-ZCRGAIPPSA-N arglabin Chemical compound C1C[C@H]2C(=C)C(=O)O[C@@H]2[C@@H]2C(C)=CC[C@]32O[C@]31C UVJYAKBJSGRTHA-ZCRGAIPPSA-N 0.000 description 1
- UVJYAKBJSGRTHA-UHFFFAOYSA-N arglabin Natural products C1CC2C(=C)C(=O)OC2C2C(C)=CCC32OC31C UVJYAKBJSGRTHA-UHFFFAOYSA-N 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- GOLCXWYRSKYTSP-UHFFFAOYSA-N arsenic trioxide Inorganic materials O1[As]2O[As]1O2 GOLCXWYRSKYTSP-UHFFFAOYSA-N 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 229950003620 asoprisnil Drugs 0.000 description 1
- GJMNAFGEUJBOCE-MEQIQULJSA-N asoprisnil Chemical compound C1([C@@H]2C3=C4CCC(=O)C=C4CC[C@H]3[C@@H]3CC[C@]([C@]3(C2)C)(COC)OC)=CC=C(\C=N\O)C=C1 GJMNAFGEUJBOCE-MEQIQULJSA-N 0.000 description 1
- 229950004810 atamestane Drugs 0.000 description 1
- PEPMWUSGRKINHX-TXTPUJOMSA-N atamestane Chemical compound C1C[C@@H]2[C@@]3(C)C(C)=CC(=O)C=C3CC[C@H]2[C@@H]2CCC(=O)[C@]21C PEPMWUSGRKINHX-TXTPUJOMSA-N 0.000 description 1
- 229950010993 atrasentan Drugs 0.000 description 1
- MOTJMGVDPWRKOC-QPVYNBJUSA-N atrasentan Chemical compound C1([C@H]2[C@@H]([C@H](CN2CC(=O)N(CCCC)CCCC)C=2C=C3OCOC3=CC=2)C(O)=O)=CC=C(OC)C=C1 MOTJMGVDPWRKOC-QPVYNBJUSA-N 0.000 description 1
- 229940120638 avastin Drugs 0.000 description 1
- 229960002756 azacitidine Drugs 0.000 description 1
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 1
- 229960002170 azathioprine Drugs 0.000 description 1
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
- JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical compound C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 229960004365 benzoic acid Drugs 0.000 description 1
- DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- AKUJBENLRBOFTD-QZIXMDIESA-N betamethasone acetate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(C)=O)(O)[C@@]1(C)C[C@@H]2O AKUJBENLRBOFTD-QZIXMDIESA-N 0.000 description 1
- 229960004648 betamethasone acetate Drugs 0.000 description 1
- PLCQGRYPOISRTQ-LWCNAHDDSA-L betamethasone sodium phosphate Chemical compound [Na+].[Na+].C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COP([O-])([O-])=O)(O)[C@@]1(C)C[C@@H]2O PLCQGRYPOISRTQ-LWCNAHDDSA-L 0.000 description 1
- 229960005354 betamethasone sodium phosphate Drugs 0.000 description 1
- 229960002938 bexarotene Drugs 0.000 description 1
- 229960004395 bleomycin sulfate Drugs 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- RJTANRZEWTUVMA-UHFFFAOYSA-N boron;n-methylmethanamine Chemical compound [B].CNC RJTANRZEWTUVMA-UHFFFAOYSA-N 0.000 description 1
- 229960001467 bortezomib Drugs 0.000 description 1
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 229940074995 bromine Drugs 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 229960002092 busulfan Drugs 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- SKKTUOZKZKCGTB-UHFFFAOYSA-N butyl carbamate Chemical compound CCCCOC(N)=O SKKTUOZKZKCGTB-UHFFFAOYSA-N 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 229960004015 calcitonin Drugs 0.000 description 1
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 1
- GMRQFYUYWCNGIN-NKMMMXOESA-N calcitriol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C GMRQFYUYWCNGIN-NKMMMXOESA-N 0.000 description 1
- KVUAALJSMIVURS-ZEDZUCNESA-L calcium folinate Chemical compound [Ca+2].C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC([O-])=O)C([O-])=O)C=C1 KVUAALJSMIVURS-ZEDZUCNESA-L 0.000 description 1
- 229940078480 calcium levulinate Drugs 0.000 description 1
- 229960004117 capecitabine Drugs 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-N carbonic acid monoamide Natural products NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 description 1
- 229960004562 carboplatin Drugs 0.000 description 1
- 229960005243 carmustine Drugs 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 229940047495 celebrex Drugs 0.000 description 1
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 1
- 230000012820 cell cycle checkpoint Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 229960005395 cetuximab Drugs 0.000 description 1
- UKTAZPQNNNJVKR-KJGYPYNMSA-N chembl2368925 Chemical compound C1=CC=C2C(C(O[C@@H]3C[C@@H]4C[C@H]5C[C@@H](N4CC5=O)C3)=O)=CNC2=C1 UKTAZPQNNNJVKR-KJGYPYNMSA-N 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229960004630 chlorambucil Drugs 0.000 description 1
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- NEHMKBQYUWJMIP-NJFSPNSNSA-N chloro(114C)methane Chemical compound [14CH3]Cl NEHMKBQYUWJMIP-NJFSPNSNSA-N 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- RRGUKTPIGVIEKM-UHFFFAOYSA-N cilostazol Chemical compound C=1C=C2NC(=O)CCC2=CC=1OCCCCC1=NN=NN1C1CCCCC1 RRGUKTPIGVIEKM-UHFFFAOYSA-N 0.000 description 1
- 229960004588 cilostazol Drugs 0.000 description 1
- DERZBLKQOCDDDZ-JLHYYAGUSA-N cinnarizine Chemical compound C1CN(C(C=2C=CC=CC=2)C=2C=CC=CC=2)CCN1C\C=C\C1=CC=CC=C1 DERZBLKQOCDDDZ-JLHYYAGUSA-N 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 229960001214 clofibrate Drugs 0.000 description 1
- KNHUKKLJHYUCFP-UHFFFAOYSA-N clofibrate Chemical compound CCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 KNHUKKLJHYUCFP-UHFFFAOYSA-N 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 150000001879 copper Chemical class 0.000 description 1
- 229960004544 cortisone Drugs 0.000 description 1
- 229940111134 coxibs Drugs 0.000 description 1
- LDHQCZJRKDOVOX-NSCUHMNNSA-N crotonic acid Chemical compound C\C=C\C(O)=O LDHQCZJRKDOVOX-NSCUHMNNSA-N 0.000 description 1
- 229940043378 cyclin-dependent kinase inhibitor Drugs 0.000 description 1
- MFNYBOWJWGPXFM-UHFFFAOYSA-N cyclobutanecarboxamide Chemical compound NC(=O)C1CCC1 MFNYBOWJWGPXFM-UHFFFAOYSA-N 0.000 description 1
- HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical compound OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 description 1
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 229960000978 cyproterone acetate Drugs 0.000 description 1
- UWFYSQMTEOIJJG-FDTZYFLXSA-N cyproterone acetate Chemical compound C1=C(Cl)C2=CC(=O)[C@@H]3C[C@@H]3[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 UWFYSQMTEOIJJG-FDTZYFLXSA-N 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 239000000824 cytostatic agent Substances 0.000 description 1
- 230000001085 cytostatic effect Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 239000002619 cytotoxin Substances 0.000 description 1
- 229960003901 dacarbazine Drugs 0.000 description 1
- 229960000640 dactinomycin Drugs 0.000 description 1
- 229960003603 decitabine Drugs 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960004833 dexamethasone phosphate Drugs 0.000 description 1
- VQODGRNSFPNSQE-CXSFZGCWSA-N dexamethasone phosphate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)COP(O)(O)=O)(O)[C@@]1(C)C[C@@H]2O VQODGRNSFPNSQE-CXSFZGCWSA-N 0.000 description 1
- LRCZQSDQZJBHAF-PUBGEWHCSA-N dha-paclitaxel Chemical compound N([C@H]([C@@H](OC(=O)CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CC)C(=O)O[C@@H]1C(=C2[C@@H](OC(C)=O)C(=O)[C@]3(C)[C@@H](O)C[C@H]4OC[C@]4([C@H]3[C@H](OC(=O)C=3C=CC=CC=3)[C@](C2(C)C)(O)C1)OC(C)=O)C)C=1C=CC=CC=1)C(=O)C1=CC=CC=C1 LRCZQSDQZJBHAF-PUBGEWHCSA-N 0.000 description 1
- 125000004663 dialkyl amino group Chemical group 0.000 description 1
- 150000004985 diamines Chemical class 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- RGLYKWWBQGJZGM-ISLYRVAYSA-N diethylstilbestrol Chemical compound C=1C=C(O)C=CC=1C(/CC)=C(\CC)C1=CC=C(O)C=C1 RGLYKWWBQGJZGM-ISLYRVAYSA-N 0.000 description 1
- 229960000452 diethylstilbestrol Drugs 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 125000005047 dihydroimidazolyl group Chemical group N1(CNC=C1)* 0.000 description 1
- 125000005048 dihydroisoxazolyl group Chemical group O1N(CC=C1)* 0.000 description 1
- 125000005049 dihydrooxadiazolyl group Chemical group O1N(NC=C1)* 0.000 description 1
- 125000005050 dihydrooxazolyl group Chemical group O1C(NC=C1)* 0.000 description 1
- 125000005051 dihydropyrazinyl group Chemical group N1(CC=NC=C1)* 0.000 description 1
- 125000004925 dihydropyridyl group Chemical group N1(CC=CC=C1)* 0.000 description 1
- 125000005053 dihydropyrimidinyl group Chemical group N1(CN=CC=C1)* 0.000 description 1
- 125000005054 dihydropyrrolyl group Chemical group [H]C1=C([H])C([H])([H])C([H])([H])N1* 0.000 description 1
- 125000005056 dihydrothiazolyl group Chemical group S1C(NC=C1)* 0.000 description 1
- 125000005057 dihydrothienyl group Chemical group S1C(CC=C1)* 0.000 description 1
- 125000005058 dihydrotriazolyl group Chemical group N1(NNC=C1)* 0.000 description 1
- HSUGRBWQSSZJOP-RTWAWAEBSA-N diltiazem Chemical compound C1=CC(OC)=CC=C1[C@H]1[C@@H](OC(C)=O)C(=O)N(CCN(C)C)C2=CC=CC=C2S1 HSUGRBWQSSZJOP-RTWAWAEBSA-N 0.000 description 1
- 229960004166 diltiazem Drugs 0.000 description 1
- PXEDJBXQKAGXNJ-QTNFYWBSSA-L disodium L-glutamate Chemical compound [Na+].[Na+].[O-]C(=O)[C@@H](N)CCC([O-])=O PXEDJBXQKAGXNJ-QTNFYWBSSA-L 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000003534 dna topoisomerase inhibitor Substances 0.000 description 1
- 229960003668 docetaxel Drugs 0.000 description 1
- 229960003413 dolasetron Drugs 0.000 description 1
- 231100000371 dose-limiting toxicity Toxicity 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 229940042317 doxorubicin liposome Drugs 0.000 description 1
- 239000002359 drug metabolite Substances 0.000 description 1
- 229950001287 edotecarin Drugs 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 229960003265 epirubicin hydrochloride Drugs 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 229940105423 erythropoietin Drugs 0.000 description 1
- IIUMCNJTGSMNRO-VVSKJQCTSA-L estramustine sodium phosphate Chemical compound [Na+].[Na+].ClCCN(CCCl)C(=O)OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)OP([O-])([O-])=O)[C@@H]4[C@@H]3CCC2=C1 IIUMCNJTGSMNRO-VVSKJQCTSA-L 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 239000002834 estrogen receptor modulator Substances 0.000 description 1
- VUCAHVBMSFIGAI-ZFINNJDLSA-M estrone sodium sulfate Chemical compound [Na+].[O-]S(=O)(=O)OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 VUCAHVBMSFIGAI-ZFINNJDLSA-M 0.000 description 1
- AFAXGSQYZLGZPG-UHFFFAOYSA-N ethanedisulfonic acid Chemical compound OS(=O)(=O)CCS(O)(=O)=O AFAXGSQYZLGZPG-UHFFFAOYSA-N 0.000 description 1
- 229960002568 ethinylestradiol Drugs 0.000 description 1
- XXRLJXZVZZXDPP-UHFFFAOYSA-N ethyl 2-chloro-2-phenylacetate Chemical compound CCOC(=O)C(Cl)C1=CC=CC=C1 XXRLJXZVZZXDPP-UHFFFAOYSA-N 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229950011548 fadrozole Drugs 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 229950003662 fenretinide Drugs 0.000 description 1
- ODKNJVUHOIMIIZ-RRKCRQDMSA-N floxuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ODKNJVUHOIMIIZ-RRKCRQDMSA-N 0.000 description 1
- RFHAOTPXVQNOHP-UHFFFAOYSA-N fluconazole Chemical compound C1=NC=NN1CC(C=1C(=CC(F)=CC=1)F)(O)CN1C=NC=N1 RFHAOTPXVQNOHP-UHFFFAOYSA-N 0.000 description 1
- 229960004884 fluconazole Drugs 0.000 description 1
- 229960000390 fludarabine Drugs 0.000 description 1
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 1
- 238000001917 fluorescence detection Methods 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- MKXKFYHWDHIYRV-UHFFFAOYSA-N flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 description 1
- 229960002074 flutamide Drugs 0.000 description 1
- 235000008191 folinic acid Nutrition 0.000 description 1
- 239000011672 folinic acid Substances 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 229960002258 fulvestrant Drugs 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 108010074605 gamma-Globulins Proteins 0.000 description 1
- 229920000370 gamma-poly(glutamate) polymer Polymers 0.000 description 1
- 201000011243 gastrointestinal stromal tumor Diseases 0.000 description 1
- 229960005277 gemcitabine Drugs 0.000 description 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 1
- 229960000578 gemtuzumab Drugs 0.000 description 1
- 229940087158 gilotrif Drugs 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 229940046240 glucomannan Drugs 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 229960002989 glutamic acid Drugs 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 229960002913 goserelin Drugs 0.000 description 1
- 230000009422 growth inhibiting effect Effects 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 229960004931 histamine dihydrochloride Drugs 0.000 description 1
- PPZMYIBUHIPZOS-UHFFFAOYSA-N histamine dihydrochloride Chemical compound Cl.Cl.NCCC1=CN=CN1 PPZMYIBUHIPZOS-UHFFFAOYSA-N 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 229960002885 histidine Drugs 0.000 description 1
- 102000044890 human EPO Human genes 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- DQOCFCZRZOAIBN-WZHZPDAFSA-L hydroxycobalamin Chemical compound O.[Co+2].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O DQOCFCZRZOAIBN-WZHZPDAFSA-L 0.000 description 1
- 229940015872 ibandronate Drugs 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 229960000908 idarubicin Drugs 0.000 description 1
- 229960001101 ifosfamide Drugs 0.000 description 1
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 1
- 229960002411 imatinib Drugs 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229940090044 injection Drugs 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 229960001388 interferon-beta Drugs 0.000 description 1
- 229940117681 interleukin-12 Drugs 0.000 description 1
- 229940065638 intron a Drugs 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 229940084651 iressa Drugs 0.000 description 1
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 1
- 229960004768 irinotecan Drugs 0.000 description 1
- 159000000014 iron salts Chemical class 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 229940045996 isethionic acid Drugs 0.000 description 1
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 229960005280 isotretinoin Drugs 0.000 description 1
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 1
- FABUFPQFXZVHFB-CFWQTKTJSA-N ixabepilone Chemical compound C/C([C@@H]1C[C@@H]2O[C@]2(C)CCC[C@@H]([C@@H]([C@H](C)C(=O)C(C)(C)[C@H](O)CC(=O)N1)O)C)=C\C1=CSC(C)=N1 FABUFPQFXZVHFB-CFWQTKTJSA-N 0.000 description 1
- 229960002014 ixabepilone Drugs 0.000 description 1
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 1
- 229940043355 kinase inhibitor Drugs 0.000 description 1
- TYQCGQRIZGCHNB-JLAZNSOCSA-N l-ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(O)=C(O)C1=O TYQCGQRIZGCHNB-JLAZNSOCSA-N 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 108010021336 lanreotide Proteins 0.000 description 1
- 229960002437 lanreotide Drugs 0.000 description 1
- 229910052746 lanthanum Inorganic materials 0.000 description 1
- FZLIPJUXYLNCLC-UHFFFAOYSA-N lanthanum atom Chemical compound [La] FZLIPJUXYLNCLC-UHFFFAOYSA-N 0.000 description 1
- GXESHMAMLJKROZ-IAPPQJPRSA-N lasofoxifene Chemical compound C1([C@@H]2[C@@H](C3=CC=C(C=C3CC2)O)C=2C=CC(OCCN3CCCC3)=CC=2)=CC=CC=C1 GXESHMAMLJKROZ-IAPPQJPRSA-N 0.000 description 1
- 229960002367 lasofoxifene Drugs 0.000 description 1
- GOTYRUGSSMKFNF-UHFFFAOYSA-N lenalidomide Chemical compound C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O GOTYRUGSSMKFNF-UHFFFAOYSA-N 0.000 description 1
- 229960003881 letrozole Drugs 0.000 description 1
- HPJKCIUCZWXJDR-UHFFFAOYSA-N letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 description 1
- 229960003136 leucine Drugs 0.000 description 1
- 229960001691 leucovorin Drugs 0.000 description 1
- 229960001614 levamisole Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 229910003002 lithium salt Inorganic materials 0.000 description 1
- 159000000002 lithium salts Chemical class 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 229960002247 lomustine Drugs 0.000 description 1
- 229960003538 lonidamine Drugs 0.000 description 1
- WDRYRZXSPDWGEB-UHFFFAOYSA-N lonidamine Chemical compound C12=CC=CC=C2C(C(=O)O)=NN1CC1=CC=C(Cl)C=C1Cl WDRYRZXSPDWGEB-UHFFFAOYSA-N 0.000 description 1
- 201000005249 lung adenocarcinoma Diseases 0.000 description 1
- 201000005243 lung squamous cell carcinoma Diseases 0.000 description 1
- 108010078259 luprolide acetate gel depot Proteins 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229960004961 mechlorethamine Drugs 0.000 description 1
- HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical class ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 1
- 229960005321 mecobalamin Drugs 0.000 description 1
- 229960002985 medroxyprogesterone acetate Drugs 0.000 description 1
- PSGAAPLEWMOORI-PEINSRQWSA-N medroxyprogesterone acetate Chemical compound C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2CC[C@]2(C)[C@@](OC(C)=O)(C(C)=O)CC[C@H]21 PSGAAPLEWMOORI-PEINSRQWSA-N 0.000 description 1
- 229960004296 megestrol acetate Drugs 0.000 description 1
- RQZAXGRLVPAYTJ-GQFGMJRRSA-N megestrol acetate Chemical compound C1=C(C)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 RQZAXGRLVPAYTJ-GQFGMJRRSA-N 0.000 description 1
- 229960001924 melphalan Drugs 0.000 description 1
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
- 229960001428 mercaptopurine Drugs 0.000 description 1
- 229960004635 mesna Drugs 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- YUUAYBAIHCDHHD-UHFFFAOYSA-N methyl 5-aminolevulinate Chemical compound COC(=O)CCC(=O)CN YUUAYBAIHCDHHD-UHFFFAOYSA-N 0.000 description 1
- 229960005033 methyl aminolevulinate Drugs 0.000 description 1
- 125000006431 methyl cyclopropyl group Chemical group 0.000 description 1
- JEWJRMKHSMTXPP-BYFNXCQMSA-M methylcobalamin Chemical compound C[Co+]N([C@]1([H])[C@H](CC(N)=O)[C@]\2(CCC(=O)NC[C@H](C)OP(O)(=O)OC3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)C)C/2=C(C)\C([C@H](C/2(C)C)CCC(N)=O)=N\C\2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O JEWJRMKHSMTXPP-BYFNXCQMSA-M 0.000 description 1
- 235000007672 methylcobalamin Nutrition 0.000 description 1
- 239000011585 methylcobalamin Substances 0.000 description 1
- 229960001566 methyltestosterone Drugs 0.000 description 1
- JMUHBNWAORSSBD-WKYWBUFDSA-N mifamurtide Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCCCCCCCCCC)COP(O)(=O)OCCNC(=O)[C@H](C)NC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)OC(O)[C@@H]1NC(C)=O JMUHBNWAORSSBD-WKYWBUFDSA-N 0.000 description 1
- 229960005225 mifamurtide Drugs 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- PQLXHQMOHUQAKB-UHFFFAOYSA-N miltefosine Chemical compound CCCCCCCCCCCCCCCCOP([O-])(=O)OCC[N+](C)(C)C PQLXHQMOHUQAKB-UHFFFAOYSA-N 0.000 description 1
- 229960003775 miltefosine Drugs 0.000 description 1
- 229960004023 minocycline Drugs 0.000 description 1
- DYKFCLLONBREIL-KVUCHLLUSA-N minocycline Chemical compound C([C@H]1C2)C3=C(N(C)C)C=CC(O)=C3C(=O)C1=C(O)[C@@]1(O)[C@@H]2[C@H](N(C)C)C(O)=C(C(N)=O)C1=O DYKFCLLONBREIL-KVUCHLLUSA-N 0.000 description 1
- 239000002829 mitogen activated protein kinase inhibitor Substances 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 1
- 229960001156 mitoxantrone Drugs 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000011242 molecular targeted therapy Methods 0.000 description 1
- 235000013923 monosodium glutamate Nutrition 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- LNOPIUAQISRISI-UHFFFAOYSA-N n'-hydroxy-2-propan-2-ylsulfonylethanimidamide Chemical compound CC(C)S(=O)(=O)CC(N)=NO LNOPIUAQISRISI-UHFFFAOYSA-N 0.000 description 1
- RWHUEXWOYVBUCI-ITQXDASVSA-N nafarelin Chemical compound C([C@@H](C(=O)N[C@H](CC=1C=C2C=CC=CC2=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 RWHUEXWOYVBUCI-ITQXDASVSA-N 0.000 description 1
- 229960002333 nafarelin Drugs 0.000 description 1
- 229940029345 neupogen Drugs 0.000 description 1
- XWXYUMMDTVBTOU-UHFFFAOYSA-N nilutamide Chemical compound O=C1C(C)(C)NC(=O)N1C1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 XWXYUMMDTVBTOU-UHFFFAOYSA-N 0.000 description 1
- 229960002653 nilutamide Drugs 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 229960000770 ondansetron hydrochloride Drugs 0.000 description 1
- 238000005580 one pot reaction Methods 0.000 description 1
- 239000011022 opal Substances 0.000 description 1
- 229940100688 oral solution Drugs 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 description 1
- 229960001756 oxaliplatin Drugs 0.000 description 1
- 125000003566 oxetanyl group Chemical group 0.000 description 1
- 125000001820 oxy group Chemical group [*:1]O[*:2] 0.000 description 1
- OLDRWYVIKMSFFB-SSPJITILSA-N palonosetron hydrochloride Chemical compound Cl.C1N(CC2)CCC2[C@@H]1N1C(=O)C(C=CC=C2CCC3)=C2[C@H]3C1 OLDRWYVIKMSFFB-SSPJITILSA-N 0.000 description 1
- 229960003359 palonosetron hydrochloride Drugs 0.000 description 1
- WLJNZVDCPSBLRP-UHFFFAOYSA-N pamoic acid Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- MPNNOLHYOHFJKL-UHFFFAOYSA-N peroxyphosphoric acid Chemical compound OOP(O)(O)=O MPNNOLHYOHFJKL-UHFFFAOYSA-N 0.000 description 1
- 238000009520 phase I clinical trial Methods 0.000 description 1
- 229960003893 phenacetin Drugs 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229940043441 phosphoinositide 3-kinase inhibitor Drugs 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 229960001416 pilocarpine Drugs 0.000 description 1
- 229960002139 pilocarpine hydrochloride Drugs 0.000 description 1
- RNAICSBVACLLGM-GNAZCLTHSA-N pilocarpine hydrochloride Chemical compound Cl.C1OC(=O)[C@@H](CC)[C@H]1CC1=CN=CN1C RNAICSBVACLLGM-GNAZCLTHSA-N 0.000 description 1
- 229960001221 pirarubicin Drugs 0.000 description 1
- 229940096701 plain lipid modifying drug hmg coa reductase inhibitors Drugs 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 229920000768 polyamine Polymers 0.000 description 1
- 125000003367 polycyclic group Chemical group 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004032 porphyrins Chemical class 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 229940063238 premarin Drugs 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 229960000624 procarbazine Drugs 0.000 description 1
- CPTBDICYNRMXFX-UHFFFAOYSA-N procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 239000003207 proteasome inhibitor Substances 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 239000003197 protein kinase B inhibitor Substances 0.000 description 1
- 239000003909 protein kinase inhibitor Substances 0.000 description 1
- 230000006337 proteolytic cleavage Effects 0.000 description 1
- VTGOHKSTWXHQJK-UHFFFAOYSA-N pyrimidin-2-ol Chemical compound OC1=NC=CC=N1 VTGOHKSTWXHQJK-UHFFFAOYSA-N 0.000 description 1
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 229960004622 raloxifene Drugs 0.000 description 1
- GZUITABIAKMVPG-UHFFFAOYSA-N raloxifene Chemical compound C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 GZUITABIAKMVPG-UHFFFAOYSA-N 0.000 description 1
- 229960004432 raltitrexed Drugs 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 201000006845 reticulosarcoma Diseases 0.000 description 1
- 208000029922 reticulum cell sarcoma Diseases 0.000 description 1
- 229930002330 retinoic acid Natural products 0.000 description 1
- 102000027483 retinoid hormone receptors Human genes 0.000 description 1
- 108091008679 retinoid hormone receptors Proteins 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 125000006413 ring segment Chemical group 0.000 description 1
- 229960004641 rituximab Drugs 0.000 description 1
- 239000003419 rna directed dna polymerase inhibitor Substances 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 229960005399 satraplatin Drugs 0.000 description 1
- 190014017285 satraplatin Chemical compound 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 239000000849 selective androgen receptor modulator Substances 0.000 description 1
- 229960003440 semustine Drugs 0.000 description 1
- 229960001153 serine Drugs 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 235000003513 sheep sorrel Nutrition 0.000 description 1
- XGVXKJKTISMIOW-ZDUSSCGKSA-N simurosertib Chemical compound N1N=CC(C=2SC=3C(=O)NC(=NC=3C=2)[C@H]2N3CCC(CC3)C2)=C1C XGVXKJKTISMIOW-ZDUSSCGKSA-N 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 208000000587 small cell lung carcinoma Diseases 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 229940073490 sodium glutamate Drugs 0.000 description 1
- JDBNUMXMGTYDDY-UHFFFAOYSA-N sodium;decan-1-olate Chemical compound [Na+].CCCCCCCCCC[O-] JDBNUMXMGTYDDY-UHFFFAOYSA-N 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000009168 stem cell therapy Methods 0.000 description 1
- 238000009580 stem-cell therapy Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 229960001052 streptozocin Drugs 0.000 description 1
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 229950000244 sulfanilic acid Drugs 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 229940120982 tarceva Drugs 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229960004964 temozolomide Drugs 0.000 description 1
- 229960000235 temsirolimus Drugs 0.000 description 1
- 229960001278 teniposide Drugs 0.000 description 1
- NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 1
- CMIBWIAICVBURI-ZETCQYMHSA-N tert-butyl (3s)-3-aminopyrrolidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CC[C@H](N)C1 CMIBWIAICVBURI-ZETCQYMHSA-N 0.000 description 1
- FEYLUKDSKVSMSZ-UHFFFAOYSA-N tert-butyl n-(4-aminocyclohexyl)carbamate Chemical compound CC(C)(C)OC(=O)NC1CCC(N)CC1 FEYLUKDSKVSMSZ-UHFFFAOYSA-N 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- 229960001712 testosterone propionate Drugs 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000003507 tetrahydrothiofenyl group Chemical group 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 229960004559 theobromine Drugs 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 229960001196 thiotepa Drugs 0.000 description 1
- PHWBOXQYWZNQIN-UHFFFAOYSA-N ticlopidine Chemical compound ClC1=CC=CC=C1CN1CC(C=CS2)=C2CC1 PHWBOXQYWZNQIN-UHFFFAOYSA-N 0.000 description 1
- 229960005001 ticlopidine Drugs 0.000 description 1
- 229960005324 tiludronic acid Drugs 0.000 description 1
- 229960003087 tioguanine Drugs 0.000 description 1
- MNRILEROXIRVNJ-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=NC=N[C]21 MNRILEROXIRVNJ-UHFFFAOYSA-N 0.000 description 1
- PLHJCIYEEKOWNM-HHHXNRCGSA-N tipifarnib Chemical compound CN1C=NC=C1[C@](N)(C=1C=C2C(C=3C=C(Cl)C=CC=3)=CC(=O)N(C)C2=CC=1)C1=CC=C(Cl)C=C1 PLHJCIYEEKOWNM-HHHXNRCGSA-N 0.000 description 1
- 229950009158 tipifarnib Drugs 0.000 description 1
- KJAMZCVTJDTESW-UHFFFAOYSA-N tiracizine Chemical compound C1CC2=CC=CC=C2N(C(=O)CN(C)C)C2=CC(NC(=O)OCC)=CC=C21 KJAMZCVTJDTESW-UHFFFAOYSA-N 0.000 description 1
- 229950002376 tirapazamine Drugs 0.000 description 1
- QVMPZNRFXAKISM-UHFFFAOYSA-N tirapazamine Chemical compound C1=CC=C2[N+]([O-])=NC(=N)N(O)C2=C1 QVMPZNRFXAKISM-UHFFFAOYSA-N 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 229940044693 topoisomerase inhibitor Drugs 0.000 description 1
- 229960000303 topotecan Drugs 0.000 description 1
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 1
- LDHQCZJRKDOVOX-UHFFFAOYSA-N trans-crotonic acid Natural products CC=CC(O)=O LDHQCZJRKDOVOX-UHFFFAOYSA-N 0.000 description 1
- 239000003558 transferase inhibitor Substances 0.000 description 1
- 229960000575 trastuzumab Drugs 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
- 229940086542 triethylamine Drugs 0.000 description 1
- YFTHZRPMJXBUME-UHFFFAOYSA-N tripropylamine Chemical compound CCCN(CCC)CCC YFTHZRPMJXBUME-UHFFFAOYSA-N 0.000 description 1
- 229960000434 triptorelin acetate Drugs 0.000 description 1
- 229960000294 triptorelin pamoate Drugs 0.000 description 1
- COIOYMYWGDAQPM-UHFFFAOYSA-N tris(2-methylphenyl)phosphane Chemical compound CC1=CC=CC=C1P(C=1C(=CC=CC=1)C)C1=CC=CC=C1C COIOYMYWGDAQPM-UHFFFAOYSA-N 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 230000005909 tumor killing Effects 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- KIGCDEJCMKDBHU-NIQQUOCOSA-K ukrain Chemical compound [OH-].[OH-].[OH-].C([C@H](O)[C@@H]1C2=CC=C3OCOC3=C2C2)C3=CC=4OCOC=4C=C3[C@H]1[N+]2(C)CCNP(=S)(NCC[N+]1(C)[C@@H]2C3=CC=4OCOC=4C=C3C[C@H](O)[C@@H]2C2=CC=C3OCOC3=C2C1)NCC[N+]1(C)[C@@H]2C3=CC(OCO4)=C4C=C3C[C@H](O)[C@@H]2C2=CC=C3OCOC3=C2C1 KIGCDEJCMKDBHU-NIQQUOCOSA-K 0.000 description 1
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 description 1
- 229940045145 uridine Drugs 0.000 description 1
- 229940005605 valeric acid Drugs 0.000 description 1
- 229960000653 valrubicin Drugs 0.000 description 1
- ZOCKGBMQLCSHFP-KQRAQHLDSA-N valrubicin Chemical compound O([C@H]1C[C@](CC2=C(O)C=3C(=O)C4=CC=CC(OC)=C4C(=O)C=3C(O)=C21)(O)C(=O)COC(=O)CCCC)[C@H]1C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O1 ZOCKGBMQLCSHFP-KQRAQHLDSA-N 0.000 description 1
- 229960002730 vapreotide Drugs 0.000 description 1
- 108700029852 vapreotide Proteins 0.000 description 1
- 229950000578 vatalanib Drugs 0.000 description 1
- YCOYDOIWSSHVCK-UHFFFAOYSA-N vatalanib Chemical compound C1=CC(Cl)=CC=C1NC(C1=CC=CC=C11)=NN=C1CC1=CC=NC=C1 YCOYDOIWSSHVCK-UHFFFAOYSA-N 0.000 description 1
- 229960003895 verteporfin Drugs 0.000 description 1
- ZQFGRJWRSLZCSQ-ZSFNYQMMSA-N verteporfin Chemical compound C=1C([C@@]2([C@H](C(=O)OC)C(=CC=C22)C(=O)OC)C)=NC2=CC(C(=C2C=C)C)=NC2=CC(C(=C2CCC(O)=O)C)=NC2=CC2=NC=1C(C)=C2CCC(=O)OC ZQFGRJWRSLZCSQ-ZSFNYQMMSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
- NMDYYWFGPIMTKO-HBVLKOHWSA-N vinflunine Chemical compound C([C@@](C1=C(C2=CC=CC=C2N1)C1)(C2=C(OC)C=C3N(C)[C@@H]4[C@@]5(C3=C2)CCN2CC=C[C@]([C@@H]52)([C@H]([C@]4(O)C(=O)OC)OC(C)=O)CC)C(=O)OC)[C@H]2C[C@@H](C(C)(F)F)CN1C2 NMDYYWFGPIMTKO-HBVLKOHWSA-N 0.000 description 1
- 229960000922 vinflunine Drugs 0.000 description 1
- GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 description 1
- 229960002066 vinorelbine Drugs 0.000 description 1
- 238000003260 vortexing Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
- ZAFYATHCZYHLPB-UHFFFAOYSA-N zolpidem Chemical compound N1=C2C=CC(C)=CN2C(CC(=O)N(C)C)=C1C1=CC=C(C)C=C1 ZAFYATHCZYHLPB-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Definitions
- the invention relates to the field of chemical medicine, in particular to a pyrimidopyridone or pyridopyridone compound and application thereof.
- Tumor molecular targeted therapy is a treatment based on the selective killing of tumor cells by chemical or biological means of key molecules closely related to tumor growth.
- the characteristics of targeted therapy are: high specificity, strong selectivity, and mild side effects; when combined, it can enhance the efficacy of traditional chemotherapy and radiotherapy and reduce postoperative recurrence.
- Imatinib mesylate (STI571) (Novartis, 2001), gefitinib (ZD1839) (AstraZeneca, 2003), erlotinib (OSI774) (Genentech and OSIP, 2004), sorafenib P-toluenesulfonate (Bay 43-9006) (Bayer and Onyx, 2005), sunitinib malate (SU11248) (Pfizer, 2006) and dasatinib (BMS-354825) (Bristol-Myers Squibb, The targeted drugs represented in 2006) have opened up a new era for cancer chemotherapy. Tumor-targeted therapy has developed rapidly in just a few years.
- tumor-targeted therapy is a hot spot and development trend of cancer treatment.
- EGFR Epidermal growth factor receptor
- EGFR is over-activated or continuously activated in a variety of tumor cells, such as lung cancer, breast cancer, prostate cancer, and the like.
- tumor cells such as lung cancer, breast cancer, prostate cancer, and the like.
- EGFR small molecule inhibitors Gefitinib and Erlotinib which were marketed in 2003-2004, have been used in the treatment of advanced non-small cell lung cancer, further clarifying that EGFR is an effective target for the treatment of non-small cell lung cancer.
- the first generation of EGFR small molecule inhibitors achieved significant clinical efficacy in patients with EGFR-sensitive mutations, prolonging their survival. However, most patients will develop resistance after 10 to 12 months of drug use. Among them, more than 50% of drug-resistant patients (carrying EGFR-sensitive mutations) are due to EGFR mutations in T790M. Compared with the L858R-sensitive mutant EGFR, the L858R/T790M secondary mutation of EGFR has a stronger affinity for ATP, and the first generation of drugs are ATP competitive inhibitors, thus leading to drug resistance.
- Osimertinib The third generation of the irreversible inhibitor Osimertinib (AZD9291), which overcomes the resistance of EGFRT790M, was approved by the US FDA in November 2015 (Cancer discovery 2014, 4(9), 1046-1061), which is clinically effective.
- EGFR Epidermal growth factor receptor
- Osimertinib has achieved great success in the clinical treatment of EGFRT790M-mutant non-small cell lung cancer, some beneficiated patients have developed resistance after 9 to 14 months of treatment (Nature Medicine 2015, 21(6), 560-2).
- the present invention provides a novel class of pyrimidopyridones or pyridopyridones which selectively inhibit the activity of mutant EGFR and overcome the resistance of existing EGFR tyrosine kinase inhibitors. Sexual problems.
- X is selected from: CH or N;
- W is selected from: H, D, CH 3 , CD 3 , CF 3 , CH 2 F, CHF 2 , F, Cl, Br, C 2 -C 5 alkyl, C 3 -C 6 cycloalkyl, substituted C 3 -C 6 cycloalkyl;
- L is selected from:
- n is selected from an integer between 1 and 8;
- n is selected from 0, 1, 2, 3;
- n is selected from 0, 1, 2, 3;
- R 1 is selected from:
- R 4 is selected from C 1 -C 6 alkyl, C 3 -C 6 cycloalkyl;
- Y is selected from the group consisting of halogen, hydroxy, amino, (N-methyl)amino, (N,N-dimethyl)amino;
- R 2 is selected from:
- n is selected from the group consisting of 0, 1 , 2;
- a 1 , A 2 , A 3 , A 4 , and A 5 are independently selected from:
- R 5 and R 6 are each independently selected from the group consisting of C 1 -C 5 alkyl, C 3 -C 6 cycloalkyl, substituted C 3 -C 6 cycloalkyl, and R 5 and R 6 are cyclized to contain 1 a 4-8-membered saturated heterocyclic ring of 3 hetero atoms, a 4-8-membered aromatic heterocyclic ring having 1-3 hetero atoms formed by cyclization of R 5 and R 6 ;
- R 3 is selected from:
- B 1 , B 2 , B 3 , B 4 , and B 5 are independently selected from:
- R 5 and R 6 are each independently selected from substituted or unsubstituted C 1 -C 5 alkyl, C 3 -C 6 cycloalkyl, substituted C 3 -C 6 cycloalkyl, R 5 and R 6 ring a substituted or unsubstituted 4-8 membered saturated heterocyclic ring containing 1-3 heteroatoms, a substituted or unsubstituted 4-8 member having 1-3 heteroatoms formed by cyclization of R 5 with R 6 aromatic heterocycle, R 5 and R 6 together form a ring containing 1-3 heteroatoms substituted or unsubstituted 8-12 membered saturated spiro ring containing 1-3 heteroatoms R 5 and R 6 together form a ring a substituted or unsubstituted 8-12 membered saturated fused ring, a substituted or unsubstituted 8-12 membered saturated bridged ring containing 1-3 heteroatoms formed by cyclization of R 5 with R 6 ;
- a 5-12-membered saturated carbocyclic or heterocyclic ring containing 0-3 heteroatoms is formed between two adjacent substituents of B 1 , B 2 , B 3 , B 4 , and B 5 .
- the compound has the structure of formula (II):
- a 1 , A 2 , A 3 , A 4 , and A 5 are each independently selected from the group consisting of: A 1 , A 2 , A 3 , A 4 , and A 5 are independently selected from the group consisting of hydrogen and halogen.
- a 1 , A 2 , A 3 , A 4 , and A 5 are each independently selected from the group consisting of: hydrogen, halogen, C 1 -C 4 alkyl, C 3 -C 6 cycloalkyl, C 1 ⁇ C 4 alkoxy.
- a 1 , A 2 , A 3 , A 4 , and A 5 are each independently selected from the group consisting of hydrogen, chlorine, fluorine, methyl, and methoxy.
- W is selected from H, C 1 -C 5 alkyl.
- L is selected from:
- L is selected from:
- L is selected from:
- R 1 is selected from:
- R 4 is selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, cyclopropyl, n-butyl, isobutyl, tert-butyl, cyclobutyl, neopentyl, cyclopentyl, cyclohexyl .
- R 1 is selected from:
- R 4 is selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, cyclopropyl, n-butyl, isobutyl, tert-butyl, cyclobutyl, neopentyl, cyclopentyl, cyclohexyl .
- the compound has the structure of Formula III, Formula IV, Formula V, or VI:
- R 3 is selected from:
- B 1 , B 2 , B 3 , B 4 , B 5 are each independently selected from the group consisting of: H, substituted or unsubstituted C 1 -C 6 alkyl, halogen, C 1 -C 4 alkane An oxy group, a C 1 -C 3 fluoroalkyl group, a substituted ethoxy group, a substituted or unsubstituted C 4 -C 9 heterocyclic group, And esters, amides, sulfones, sulfoxides, ureas formed by the above groups;
- R 5 and R 6 are each independently selected from a substituted or unsubstituted C 1 -C 5 alkyl group, and R 5 and R 6 are cyclized to form a substituted or unsubstituted 4-8 member having 1 to 3 hetero atoms.
- R 5 and R 6 together form a ring
- R 5 and R 6 together form a ring containing 1-3 heteroatoms substituted or unsubstituted 8-12 membered saturated spiro ring containing 1 to 3 heteroatoms substituted or unsubstituted fused 8-12 membered saturated ring
- R 5 and R R 5 and R 6 together form a ring of 6 ring
- B 1 , B 2 , B 3 , B 4 , B 5 are each independently selected from the group consisting of: H, C 1 -C 6 alkyl, halogen, C 1 -C 4 alkoxy, C 1 ⁇ C 3 fluoroalkyl, N,N-dimethylaminoethoxy, N,N-dimethylaminopropoxy, 2-(N-methylpiperazinyl)ethoxy, 2-( N-acetylpiperazinyl)ethoxy, 2-morphinolinylethoxy, 2-thiophinylethoxy, 2-piperidinylethoxy, 2-tetrahydropyrrolylethoxy, N-methylpiperazinyl, N-ethylpiperazinyl, piperazinyl, (R)-3,4-dimethylpiperazinyl, (S)-3,4-dimethylpiperazinyl, 4-isopropylpiperazin-1-yl, (3S,5R)-3
- B 1 , B 2 , B 3 , B 4 , B 5 are each independently selected from the group consisting of: H, C 1 -C 3 alkyl, halogen, 4-methylpiperazin-1-yl, 4-isopropylpiperazin-1-yl, piperidinyl, 9-methyl-3,9-diazaspiro[5.5]undec-3-yl, 3-methyl-1,3-di Azepan-1-yl, (1S,4S)-5-methyl-2,5-diazabicyclo[2.2.1]hept-2-yl,(2-(dimethylamino)ethyl (M)amino, 4-(dimethylamino)piperidin-1-yl, 7-methyl-2,7-diazaspiro[3.5]decane-2-yl, (R)- 3,4-Dimethylpiperazin-1-yl, (3S,5R)-3,4,5-trimethylpiperazin-1-yl, (R)
- B 1 , B 2 , B 4 , and B 5 are each independently selected from the group consisting of: H, C 1 -C 3 alkyl, halogen; and B 3 is selected from the group consisting of: 4-methylpiperazine-1- Base, 4-isopropylpiperazin-1-yl, piperidinyl, 9-methyl-3,9-diazaspiro[5.5]undec-3-yl, 3-methyl-1,3 -diazepan-1-yl, (1S,4S)-5-methyl-2,5-diazabicyclo[2.2.1]hept-2-yl, (2-(dimethylamino) Ethyl)(methyl)amino, 4-(dimethylamino)piperidin-1-yl, 7-methyl-2,7-diazaspiro[3.5]decane-2-yl, (R -3,4-Dimethylpiperazin-1-yl, (3S,5R)-3,4,5-trimethylpiperazin-1-yl
- W is selected from the group consisting of: H, methyl; X is selected from N;
- R 1 is selected from: Wherein R 4 is selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, cyclopropyl, n-butyl, isobutyl, tert-butyl, cyclobutyl, neopentyl, cyclopentyl, and ring. Hexyl
- R 2 is selected from: Wherein n is 0; A 1 , A 2 , A 3 , A 4 , and A 5 are independently selected from the group consisting of hydrogen, chlorine, and fluorine;
- B 1 , B 2 , B 3 , B 4 , B 5 are independently selected from the group consisting of: H, methyl, halogen, 4-methylpiperazin-1-yl, piperidinyl, 9-methyl-3,9 -diazaspiro[5.5]undec-3-yl, 3-methyl-1,3-diazepan-1-yl, (1S,4S)-5-methyl-2,5 -diazabicyclo[2.2.1]heptan-2-yl, (2-(dimethylamino)ethyl)(methyl)amino, 4-(dimethylamino)piperidin-1-yl, 7 -methyl-2,7-diazaspiro[3.5]decane-2-yl, (R)-3,4-dimethylpiperazin-1-yl, (3S,5R)-3,4, 5-trimethylpiperazin-1-yl, (R)-3-methylpiperazin-1-yl, 4-(4-methylpiperazin-1-yl
- L is selected from:
- W is H;
- R 4 is selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, cyclopropyl;
- a 1 is chlorine, A 2 , A 3 , A 4 , A 5 All are hydrogen;
- B 2 is methyl,
- B 3 is 4-methylpiperazin-1-yl,
- B 1 , B 4 , B 5 are all H;
- L is selected from:
- W is methyl;
- R 4 is selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, cyclopropyl;
- a 1 is chlorine,
- a 2 , A 3 , A 4 , A 5 is hydrogen;
- B 2 is methyl,
- B 3 is 4-methylpiperazin-1-yl,
- B 1 , B 4 , B 5 are H;
- L is selected from:
- the compound is selected from the group consisting of
- the present invention also provides the use of the above pyridopyrimidinone or pyridopyridone compound or a pharmaceutically acceptable salt thereof or a stereoisomer thereof or a prodrug molecule thereof.
- the tumor is a malignant tumor of a EGFR gene mutation.
- the tumor comprises: non-small cell lung cancer, malignant melanoma, prostate cancer, kidney cancer, bladder cancer, ovarian cancer, colon cancer, rectal cancer, breast cancer, cervical cancer, lung cancer, laryngeal cancer, Nasopharyngeal carcinoma, pancreatic cancer, multiple myeloma, B lymphoma, leukemia.
- the tumor is a non-small cell lung cancer of the EGFR L858R/T790MC797S mutation.
- the invention also provides a pharmaceutical composition for preventing and treating tumors.
- a pharmaceutical composition for controlling tumors which comprises the above-mentioned pyridopyrimidinone or pyridopyridone compound or a pharmaceutically acceptable salt thereof or a stereoisomer thereof or a prodrug molecule thereof.
- the tumor is a malignant tumor of a EGFR gene mutation.
- the tumor comprises: non-small cell lung cancer, malignant melanoma, prostate cancer, kidney cancer, bladder cancer, ovarian cancer, colon cancer, rectal cancer, breast cancer, cervical cancer, lung cancer, laryngeal cancer, Nasopharyngeal carcinoma, pancreatic cancer, multiple myeloma, B lymphoma, leukemia.
- the tumor is a non-small cell lung cancer of the EGFR L858R/T790MC797S mutation.
- the compound of the present invention can selectively inhibit the activity of mutant EGFR and inhibit the other proteases of EGFR and Her family, and is a novel type of novel and capable of overcoming the resistance of existing EGFR tyrosine kinase inhibitors and is selective and A protein kinase inhibitor of good pharmacokinetic properties.
- the compounds of the present invention are effective for inhibiting the growth of a variety of tumor cells, particularly for selectively inhibiting EGFR L858R/T790MC797S lung cancer cells, and the selectivity of some preferred compounds is greater than 50-fold compared to wild-type cancer cells.
- the compounds of the present invention are useful for the preparation of antitumor drugs, and can overcome the drug resistance problems induced by existing drugs (such as gefitinib, erlotinib, especially octetinib (AZD9291)), mainly for existing The third generation of EGFR small molecule inhibitors against non-small cell lung cancer drugs Osimertinib (AZD9291), Olmutinib (HM6171), Rociletinib (9, CO-1686) induced 797th cysteine mutation into serine (C797S) Resistance.
- the compounds of the present invention are useful for preventing postoperative recurrence of various tumors, as well as further consolidating treatment, for the purpose of prolonging the survival of tumor patients, improving their quality of life, and inhibiting tumor deterioration.
- Figure 1 is a graph showing the results of a test of the effect of compound 560082 of the present invention on phosphorylation of EGFR L858R/T790M/C797S and EGFR 19D/T790M/C797S in a tool cell;
- Figure 2 is a graph showing the results of a test of the effect of Compound 580120 of the present invention on phosphorylation of EGFR L858R/T790M/C797S and EGFR 19D/T790M/C797S in a tool cell.
- any variable e.g. R 1, R, etc.
- any variable e.g. R 1, R, etc.
- combinations of substituents and variables are allowed as long as such combinations stabilize the compound.
- a line drawn from a substituent into the ring system means that the bond referred to can be attached to any ring atom that can be substituted. If the ring system is polycyclic, it means that such a bond is only attached to any suitable carbon atom of the adjacent ring. It will be appreciated that one of ordinary skill in the art can select substituents and substitution patterns for the compounds of the present invention to provide compounds which are chemically stable and which are readily synthesized from readily available starting materials by techniques in the art and the methods set forth below.
- substituent itself is substituted by more than one group, it is understood that these groups may be on the same carbon atom or on different carbon atoms as long as the structure is stabilized.
- the phrase "optionally substituted with one or more substituents” is considered to be equivalent to the phrase “optionally substituted with at least one substituent” and in this case the preferred embodiment will have 0-3 substituents.
- alkyl and alkylene as used herein are meant to include branched and straight-chain saturated aliphatic hydrocarbon groups having the specified number of carbon atoms.
- the definition of “C 1 -C 5 " in “C 1 -C 5 alkyl” includes a group having 1, 2, 3, 4, or 5 carbon atoms arranged in a straight or branched chain.
- “C 1 -C 5 alkyl” specifically includes methyl, ethyl, n-propyl, isopropyl, n-butyl, t-butyl, isobutyl, pentyl.
- cycloalkyl refers to a monocyclic saturated aliphatic hydrocarbon group having the specified number of carbon atoms.
- cycloalkyl includes cyclopropyl, methyl-cyclopropyl, 2,2-dimethyl-cyclobutyl, 2-ethyl-cyclopentyl, cyclohexyl and the like.
- heteroaryl denotes a stable monocyclic ring of up to 6 atoms in the ring or a bicyclic carbon ring of up to 6 atoms in each ring, at least one of which is an aromatic ring and contains from 1 to 4 Heteroatoms from O, N and S.
- Heteroaryl groups within the scope of this definition include, but are not limited to, imidazolyl, triazolyl, pyrazolyl, furyl, thienyl, oxazolyl, isoxazolyl, pyrazinyl, pyridazinyl, pyridyl, Pyrimidinyl, pyrrolyl.
- Heteroaryl is also understood to include any N-oxide derivative of a nitrogen-containing heteroaryl group for the definition of the following heteroaryl.
- the heteroaryl substituent is bicyclic and contains a ring which is non-aromatic or contains no heteroatoms, it is understood that each is attached via an aromatic ring or via a heteroatom-containing ring.
- heterocycle refers to a 5- to 6-membered aromatic or non-aromatic heterocyclic ring containing from 1 to 4 heteroatoms selected from O, N and S, and includes a bicyclic group. group.
- heterocyclyl thus includes the heteroaryl groups mentioned above, as well as the dihydrogenated and tetrahydrogenated analogs thereof.
- heterocyclyl include, but are not limited to, imidazolyl, indolyl, isothiazolyl, isoxazolyl, oxadiazolyl, oxazolyl, oxetanyl, pyridyl Meryl, pyrazinyl, pyrazolyl, pyridazinyl, pyridyl, pyrimidinyl, pyrrolyl, quinoxalinyl, tetrazolyl, thiadiazolyl, thiazolyl, thienyl, triazolyl, l, 4-Dioxoalkyl, pyrrolidinyl, dihydroimidazolyl, dihydroisoxazolyl, dihydroisothiazolyl, dihydrooxadiazolyl, dihydrooxazolyl, dihydropyrazinyl, dihydrogen Pyrazolyl, dihydropyridyl, di
- heterocyclic substituent can be achieved by a carbon atom or by a hetero atom.
- the heterocyclic ring is selected from the group consisting of imidazolyl, pyridyl, 1-pyrrolidone, 2-piperidone, 2-pyrimidinone, 2-pyrrolidone, thienyl, oxazolyl, triazolyl, isoxazole base.
- halo or halogen as used herein is meant to include chloro, fluoro, bromo and iodo.
- alkyl, cycloalkyl, aryl, heteroaryl and heterocyclyl substituents may be unsubstituted or substituted.
- (C 1 -C 6 )alkyl may be substituted by one, two or three substituents selected from OH, halogen, alkoxy, dialkylamino or heterocyclic groups such as morpholinyl, piperidinyl and the like. Replace.
- the invention includes the free forms of the compounds of Formulas I-VI, as well as the pharmaceutically acceptable salts and stereoisomers thereof.
- Some specific exemplary compounds herein are protonated salts of amine compounds.
- the term "free form" refers to an amine compound in a non-salt form.
- Included pharmaceutically acceptable salts include not only the exemplary salts of the particular compounds described herein, but also all of the typical pharmaceutically acceptable salts of the free forms of the compounds of Formulas I-VI.
- the free form of the particular salt of the compound can be isolated using techniques known in the art.
- the free form can be regenerated by treating the salt with a suitable dilute aqueous base such as a dilute aqueous solution of NaOH, a dilute aqueous solution of potassium carbonate, dilute aqueous ammonia, and a dilute aqueous solution of sodium bicarbonate.
- a suitable dilute aqueous base such as a dilute aqueous solution of NaOH, a dilute aqueous solution of potassium carbonate, dilute aqueous ammonia, and a dilute aqueous solution of sodium bicarbonate.
- the free form differs somewhat from its respective salt form in solubility in certain physical properties, such as in polar solvents, but for purposes of the invention such acid and base salts are otherwise pharmaceutically equivalent to their respective free forms.
- the pharmaceutically acceptable salts of the present invention can be synthesized from the compounds of the present invention containing a basic moiety or an acidic moiety by conventional chemical methods.
- salts of basic compounds are prepared by ion exchange chromatography or by reaction of a free base with a stoichiometric or excess amount of an inorganic or organic acid in the desired salt form in a suitable solvent or combination of solvents.
- a salt of an acidic compound is formed by reaction with a suitable inorganic or organic base.
- pharmaceutically acceptable salts of the compounds of the invention include the conventional non-toxic salts of the compounds of the invention which are formed by the reaction of a basic compound of the invention with an inorganic or organic acid.
- conventional non-toxic salts include those derived from inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, sulfamic acid, phosphoric acid, nitric acid, and the like, and also include organic acids such as acetic acid, propionic acid, succinic acid, glycolic acid, and hard.
- Fatty acid lactic acid, malic acid, tartaric acid, citric acid, ascorbic acid, pamoic acid, maleic acid, hydroxymaleic acid, phenylacetic acid, glutamic acid, benzoic acid, salicylic acid, p-aminobenzenesulfonic acid, 2-acetyl A salt prepared from oxy-benzoic acid, fumaric acid, toluenesulfonic acid, methanesulfonic acid, ethanedisulfonic acid, oxalic acid, isethionic acid, trifluoroacetic acid or the like.
- a suitable "pharmaceutically acceptable salt” refers to a salt prepared by pharmaceutically acceptable non-toxic bases including inorganic bases and organic bases.
- Salts derived from inorganic bases include aluminum salts, ammonium salts, calcium salts, copper salts, iron salts, ferrous salts, lithium salts, magnesium salts, manganese salts, manganese salts, potassium salts, sodium salts, zinc salts and the like. Ammonium salts, calcium salts, magnesium salts, potassium salts and sodium salts are particularly preferred.
- a salt derived from a pharmaceutically acceptable organic non-toxic base comprising a salt of a primary, secondary and tertiary amine, the substituted amine comprising a naturally occurring substituted amine, a cyclic amine and a basic ion exchange resin such as a fine Amino acid, betaine, caffeine, choline, N,N'-dibenzylethylenediamine, diethylamine, 2-diethylaminoethanol, 2-dimethylaminoethanol, aminoethanol, ethanolamine, B Diamine, N-ethylmorpholine, N-ethylpiperidine, glucosamine, glucosamine, histidine, hydroxycobalamin, isopropylamine, lysine, methylglucamine, morpholine, piperazine , piperidine, guanidine, polyamine resin, procaine, guanidine, theobromine, triethylamine, trimethylamine, tripropylamine, t
- the acidic moiety such as a carboxyl group
- a cationic moiety such as tetravalent
- the compounds of the invention are potential internal salts or zwitterions.
- the compounds of the invention can be prepared using the reactions as shown in the scheme below. Accordingly, the following illustrative schemes are for illustrative purposes and are not limited to the listed compounds or any particular substituents. The number of substituents shown in the schemes does not necessarily have to correspond to the number used in the claims, and for the sake of clarity, it is shown that the mono-substituents are attached to a compound which allows multiple substituents under the definition of formula I above.
- the compounds of formula I-VI, and pharmaceutically acceptable salts thereof, provided herein, are useful for treating transitional proliferative diseases or conditions, such as tumors in humans or other mammals.
- the compounds designed herein and pharmaceutically acceptable salts thereof can be used to treat or control non-small cell lung cancer, small cell lung cancer, lung adenocarcinoma, lung squamous cell carcinoma, pancreatic cancer, breast cancer, prostate cancer , liver cancer, skin cancer, epithelial cell carcinoma, gastrointestinal stromal tumor, leukemia, histiocytic lymphoma, nasopharyngeal carcinoma and other transitional proliferative diseases.
- Metabolites of the compounds and pharmaceutically acceptable salts thereof, and prodrugs which can be converted in vivo to the structures of the compounds and pharmaceutically acceptable salts thereof, are also included in the claims of the present application. in.
- the compounds of formula I-VI can be combined with other agents known to treat or ameliorate similar conditions.
- the mode of administration & dosage of the original drug remains unchanged, while the compound of formula I-IV is administered simultaneously or subsequently.
- the compound of formula I-IV is administered concurrently with one or more other drugs, it is preferred to use a pharmaceutical composition comprising both one or several known drugs and a compound of formula I-IV.
- Combination of drugs also includes the administration of a compound of formula I-IV with one or more other known drugs over an overlapping period of time.
- the dose of the compound of formula I-IV or a known drug may be lower than when they are administered alone.
- Drugs or active ingredients which may be combined with a compound of formula I-VI include, but are not limited to:
- the pharmaceutical or active ingredient that can be administered in combination with a compound of Formulas I-VI includes, but is not limited to, leucine, alendronate, interferon, atraxine, allopurinol, Sodium decylate, palonosetron hydrochloride, hexamethylene melamine, aminoglutamine, amifostine, amrubicin, amsacrine, anastrozole, dolasetron, aranesp, arglabin, Arsenic trioxide, anoxin, 5-azacytidine, azathioprine, BCG or tici BCG, betahidine, betamethasone acetate, betamethasone sodium phosphate, bexarotene, bleomycin sulfate, bromine Gan, bortezomib, busulfan, calcitonin, alemzumab injection, capecitabine, carboplatin, constance, cefesone, simmein, daunorubicin,
- Step 4 (S)-3-(6-(2-Chlorophenyl)-2-(methylthio)-7-oxopyrido[2,3-d]pyrimidin-8(7H)-yl) -pyrrolidine-1-carboxylic acid tert-butyl ester (5)
- Step 7 (S)-6-(2-Chlorophenyl)-2-((3-methyl-4-(4-methylpiperazin-1-yl)phenyl)amino)-8-(pyrrole) Alkan-3-yl)pyrido[2,3-d]pyrimidin-7(8H)-one (8)
- Step 8 (S)-8-(1-Acetylpyrrol-3-yl)-6-(2-chlorophenyl)-2-((3-methyl-4-(4-methylpiperazine)- 1-yl)phenyl)amino)pyrido[2,3-d]pyrimidin-7(8H)-one (560123)
- Step 9 ((1R,4R)-4-((5-Bromo-2-chloropyrimidin-4-yl)amino)cyclohexyl)carbamic acid tert-butyl ester (10) tert-butyl((1R,4R)- 4-((5-bromo-2-chloropyrimidin-4-yl)amino)cyclohexyl)carbamate
- Step 10 ((1R,4R)-4-(2-chloro-5-methyl-7-oxopyrido[2,3-d]pyrimidin-8(7H)-yl)cyclohexyl)carbamic acid Butyl ester (11)
- Step 11 ((1R,4R)-4-(6-Bromo-2-chloro-5-methyl-7-oxopyrido[2,3-d]pyrimidin-8(7H)-yl)cyclohexyl ) tert-butyl carbamate (12)
- Step 12 ((1R,4R)-4-(6-Bromo-5-methyl-2-((3-methyl-4-(4-methylpiperazin-1-yl)phenyl)amino) -7-oxopyrido[2,3-d]pyrimidine-8(7H)-yl)cyclohexyl)carbamic acid tert-butyl ester (13)
- Step 13 ((1R,4R)-4-(6-(2-Chlorophenyl)-5-methyl-2-((3-methyl-4-(4-methylpiperazin-1-yl) Phenyl)amino)-7-oxopyrido[2,3-d]pyrimidin-8(7H)-yl)cyclohexyl)carbamic acid tert-butyl ester (14)
- Step 14 8-((1R,4R)-4-Aminocyclohexyl)-6-(2-chlorophenyl)-5-methyl-2-((3-methyl-4-(4-methyl) Piperazin-1-yl)phenyl)amino)pyrido[2,3-d]pyrimidin-7(8H)-one (15)
- Step 15 N-((1R,4R)-4-(6-(2-chlorophenyl)-5-methyl-2-((3-methyl-4-(4-methylpiperazine-1) -yl)phenyl)amino)-7-oxopyrido[2,3-d]pyrimidin-8(7H)-yl)cyclohexyl)acetamide (560083)
- the synthesis method was as in Example 18, and the yield was 85.4%.
- the synthesis method was as in Example 18, and the yield was 60.6%.
- the synthesis method was as in Example 18, and the yield was 75.9%.
- the synthesis method was as in Example 18, and the yield was 85.4%.
- the synthesis method was as in Example 18, and the yield was 81.6%.
- the synthesis method was as in Example 18, and the yield was 80.9%.
- the synthesis method was as in Example 18, and the yield was 70.3%.
- the synthesis method was as in Example 18, and the yield was 85.4%.
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
L'invention concerne un composé de pyridopyrimidinone ou de pyridopyridone ayant une structure de formule (I) ou un sel pharmaceutiquement acceptable ou un stéréoisomère ou une molécule de promédicament de celui-ci. De tels composés peuvent inhiber l'activité de la 797ème mutation de cystéine en sérine mutante de l'EGFR (EGFR C797S), mais possèdent un faible impact sur l'activité de l'EGFR de type sauvage, peuvent ainsi inhiber efficacement la croissance de cellules tumorales du cancer du poumon non à petites cellules, et peuvent être utilisés pour préparer un médicament antitumoral, qui peut être principalement utilisé pour la résistance clinique de la 797ème mutation de cystéine en sérine (C797S) induite par le médicament de troisième génération existant contre le cancer du poumon non à petites cellules inhibiteur d'EGFR à petites molécules, tel que l'Osimertinib (AZD9291), Olmutinib(HM6171), Rociletinib(9,CO-1686) et analogues. Les composés sont sélectifs pour le cancer du poumon non à petites cellules de type sauvage. (I)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201880047588.2A CN110914267B (zh) | 2017-07-19 | 2018-07-17 | 嘧啶并吡啶酮或者吡啶并吡啶酮类化合物及其应用 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710591644 | 2017-07-19 | ||
CN201710591644.6 | 2017-07-19 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2019015593A1 true WO2019015593A1 (fr) | 2019-01-24 |
Family
ID=65014945
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2018/096009 WO2019015593A1 (fr) | 2017-07-19 | 2018-07-17 | Composé de pyrimidopyridone ou pyridopyridone et utilisation correspondante |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN110914267B (fr) |
WO (1) | WO2019015593A1 (fr) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112010844A (zh) * | 2019-05-31 | 2020-12-01 | 中国药科大学 | N-(嘧啶-2-基)香豆素-7-胺衍生物作为蛋白激酶抑制剂的制法和应用 |
CN112759589A (zh) * | 2019-11-01 | 2021-05-07 | 暨南大学 | 嘧啶并吡啶酮类化合物及其应用 |
WO2021139775A1 (fr) * | 2020-01-10 | 2021-07-15 | 江苏先声药业有限公司 | Composé de pyridone et son application |
JP2022546375A (ja) * | 2019-08-23 | 2022-11-04 | 北京泰徳製薬股▲フン▼有限公司 | Egfrおよびalkを阻害してそれらの分解を阻害する化合物 |
CN115353514A (zh) * | 2022-08-31 | 2022-11-18 | 河南师范大学 | 氟代吡啶并嘧啶酮类化合物及其合成方法 |
JP2023509011A (ja) * | 2019-12-31 | 2023-03-06 | 成都百裕制薬股▲ふん▼有限公司 | プリン誘導体および医薬におけるその使用 |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7098332B2 (en) * | 2002-12-20 | 2006-08-29 | Hoffmann-La Roche Inc. | 5,8-Dihydro-6H-pyrido[2,3-d]pyrimidin-7-ones |
WO2011063415A2 (fr) * | 2009-11-23 | 2011-05-26 | Afraxis, Inc. | Méthodes de traitement de trouble cognitif léger |
CN102648200A (zh) * | 2009-10-09 | 2012-08-22 | 亚弗克希斯公司 | 用于治疗cns病症的8-乙基-6-(芳基)吡啶并[2,3-d]嘧啶-7(8h)-酮 |
WO2013086451A2 (fr) * | 2011-12-09 | 2013-06-13 | Afraxis, Inc. | Inhibiteurs de pak destinés au traitement du cancer |
CN103596951A (zh) * | 2011-04-08 | 2014-02-19 | 阿弗拉克西斯控股股份有限公司 | 用于治疗神经系统障碍和癌症的8-乙基-6-(芳基)吡啶并[2,3-d]嘧啶-7(8h)-酮 |
CN105130986A (zh) * | 2015-09-30 | 2015-12-09 | 广州科擎新药开发有限公司 | 嘧啶或吡啶并吡啶酮类化合物及其应用 |
CN105307657A (zh) * | 2013-03-15 | 2016-02-03 | 西建阿维拉米斯研究公司 | 杂芳基化合物和其用途 |
CN106459034A (zh) * | 2014-02-07 | 2017-02-22 | 普林斯匹亚生物制药公司 | 作为成纤维细胞生长因子受体抑制剂的喹诺酮衍生物 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104418860B (zh) * | 2013-08-20 | 2016-09-07 | 中国科学院广州生物医药与健康研究院 | 嘧啶并杂环类化合物及其药用组合物和应用 |
-
2018
- 2018-07-17 WO PCT/CN2018/096009 patent/WO2019015593A1/fr active Application Filing
- 2018-07-17 CN CN201880047588.2A patent/CN110914267B/zh active Active
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7098332B2 (en) * | 2002-12-20 | 2006-08-29 | Hoffmann-La Roche Inc. | 5,8-Dihydro-6H-pyrido[2,3-d]pyrimidin-7-ones |
CN102648200A (zh) * | 2009-10-09 | 2012-08-22 | 亚弗克希斯公司 | 用于治疗cns病症的8-乙基-6-(芳基)吡啶并[2,3-d]嘧啶-7(8h)-酮 |
WO2011063415A2 (fr) * | 2009-11-23 | 2011-05-26 | Afraxis, Inc. | Méthodes de traitement de trouble cognitif léger |
CN103596951A (zh) * | 2011-04-08 | 2014-02-19 | 阿弗拉克西斯控股股份有限公司 | 用于治疗神经系统障碍和癌症的8-乙基-6-(芳基)吡啶并[2,3-d]嘧啶-7(8h)-酮 |
WO2013086451A2 (fr) * | 2011-12-09 | 2013-06-13 | Afraxis, Inc. | Inhibiteurs de pak destinés au traitement du cancer |
CN105307657A (zh) * | 2013-03-15 | 2016-02-03 | 西建阿维拉米斯研究公司 | 杂芳基化合物和其用途 |
CN106459034A (zh) * | 2014-02-07 | 2017-02-22 | 普林斯匹亚生物制药公司 | 作为成纤维细胞生长因子受体抑制剂的喹诺酮衍生物 |
CN105130986A (zh) * | 2015-09-30 | 2015-12-09 | 广州科擎新药开发有限公司 | 嘧啶或吡啶并吡啶酮类化合物及其应用 |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112010844A (zh) * | 2019-05-31 | 2020-12-01 | 中国药科大学 | N-(嘧啶-2-基)香豆素-7-胺衍生物作为蛋白激酶抑制剂的制法和应用 |
CN112010844B (zh) * | 2019-05-31 | 2023-07-25 | 中国药科大学 | N-(嘧啶-2-基)香豆素-7-胺衍生物作为蛋白激酶抑制剂的制法和应用 |
JP2022546375A (ja) * | 2019-08-23 | 2022-11-04 | 北京泰徳製薬股▲フン▼有限公司 | Egfrおよびalkを阻害してそれらの分解を阻害する化合物 |
CN112759589A (zh) * | 2019-11-01 | 2021-05-07 | 暨南大学 | 嘧啶并吡啶酮类化合物及其应用 |
CN112759589B (zh) * | 2019-11-01 | 2022-04-08 | 暨南大学 | 嘧啶并吡啶酮类化合物及其应用 |
JP2023509011A (ja) * | 2019-12-31 | 2023-03-06 | 成都百裕制薬股▲ふん▼有限公司 | プリン誘導体および医薬におけるその使用 |
JP7428806B2 (ja) | 2019-12-31 | 2024-02-06 | 成都百裕制薬股▲ふん▼有限公司 | プリン誘導体および医薬におけるその使用 |
WO2021139775A1 (fr) * | 2020-01-10 | 2021-07-15 | 江苏先声药业有限公司 | Composé de pyridone et son application |
CN115353514A (zh) * | 2022-08-31 | 2022-11-18 | 河南师范大学 | 氟代吡啶并嘧啶酮类化合物及其合成方法 |
CN115353514B (zh) * | 2022-08-31 | 2023-07-25 | 河南师范大学 | 氟代吡啶并嘧啶酮类化合物及其合成方法 |
Also Published As
Publication number | Publication date |
---|---|
CN110914267B (zh) | 2022-07-12 |
CN110914267A (zh) | 2020-03-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2019015593A1 (fr) | Composé de pyrimidopyridone ou pyridopyridone et utilisation correspondante | |
AU2016309833B2 (en) | Pharmaceutical composition and application replacing quinolone derivative, pharmaceutical acceptable salt, or stereoisomer | |
AU2011274192B2 (en) | Heterocyclic alkynyl benzene compounds and medical compositions and uses thereof | |
AU2015353210B2 (en) | 2-aminopyrimidine compound and pharmaceutical composition and use thereof | |
EP2746283A1 (fr) | Dérivés de pyrimidopyrimidone, compositions pharmaceutiques et leurs utilisations | |
WO2014079232A1 (fr) | Dérivés de 7-oxo-pyrimidine, compositions pharmaceutiques et utilisations de celles-ci | |
WO2022253283A1 (fr) | Agent de dégradation de protéine kinases et son utilisation | |
AU2019241374B2 (en) | Quinoline or quinazoline compound and application thereof | |
CN103374000A (zh) | 嘧啶并二氮杂卓类化合物及其药用组合物和应用 | |
CN112851667B (zh) | 含氮并杂环类化合物及其药用组合物和应用 | |
CN114539263A (zh) | 一类含氮并杂环化合物及其药用组合物和应用 | |
WO2021180008A1 (fr) | Composé cyclique tri-aromatique contenant une structure d'urée et utilisation associée | |
CN112313213B (zh) | 3-氨基吡唑类化合物及其应用 | |
CN103570731B (zh) | 嘧啶并三环或嘧啶并四环类化合物及其药用组合物和应用 | |
WO2022148317A1 (fr) | Composé de 2-aminopyrimidine et composition pharmaceutique le comprenant et application associée | |
US20230348462A1 (en) | Imidazo[4,5-c]quinoline compounds and their use as atm kinase inhibitors | |
CN118084902A (zh) | 2-氨基噻唑嘧啶并吡啶酮类化合物或药学上可接受的盐或立体异构体及制备方法和应用 | |
CN116063283A (zh) | 3-氨基吲唑类化合物及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 18834520 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 18834520 Country of ref document: EP Kind code of ref document: A1 |